name: Multiple Sclerosis
creation_date: '2025-12-04T16:57:31Z'
description: >-
  Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disease of
  the central nervous system in which autoreactive T and B lymphocytes drive
  inflammatory demyelination, axonal damage, and gliotic plaque formation in the
  brain, optic nerves, and spinal cord. Clinical courses range from
  relapsing-remitting to progressive forms, producing accumulating sensory, motor,
  visual, and cognitive disability.
category: Neurological Disorder
parents:
- Autoimmune Disorder
inheritance:
- name: Multifactorial
  description: >
    MS is not a Mendelian disorder. Susceptibility is multifactorial with
    polygenic risk (HLA-DRB1*15:01 strongest locus) and environmental factors
    (EBV infection, vitamin D deficiency).
  evidence:
  - reference: PMID:40636815
    reference_title: "Multiple sclerosis: 2024 update."
    supports: SUPPORT
    snippet: recent data point towards a role of genetics in MS disease progression
    explanation: This review acknowledges the genetic component of MS but does not explicitly describe polygenic/multifactorial inheritance; the multifactorial model is well-established from GWAS literature.
prevalence:
- population: Global
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_per_100000: 36.0
  percentage: 0.036
  notes: "Approximately 2.8 million people affected worldwide; ~36 per 100,000 globally."
  evidence:
  - reference: PMID:30679040
    reference_title: "Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016."
    supports: SUPPORT
    snippet: In 2016, there were 2 221 188 prevalent cases of multiple sclerosis ... globally, which corresponded to a 10·4% ... increase in the age-standardised prevalence since 1990
    explanation: The GBD study estimated ~2.2 million prevalent cases globally in 2016, consistent with a prevalence of approximately 36 per 100,000.
  - reference: ORPHA:802
    reference_title: "NON RARE IN EUROPE: Multiple sclerosis"
    supports: SUPPORT
    snippet: "NON RARE IN EUROPE: Multiple sclerosis"
    explanation: Orphanet classifies MS as non-rare in Europe, consistent with its relatively high prevalence.
- population: Europe
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 115.0
  percentage: 0.115
  notes: "Higher prevalence in northern European populations; approximately 115 per 100,000."
  evidence:
  - reference: PMID:37059571
    reference_title: "Incidence and prevalence of multiple sclerosis in China and other Asian countries."
    supports: SUPPORT
    snippet: Prevalence rates in countries with predominantly white populations are considerably higher and have increased over time, reaching 115 cases/100,000 population in 2015
    explanation: Prevalence in predominantly white European populations reaches approximately 115 per 100,000.
progression:
- phase: Relapsing-Remitting
  notes: Characterized by periods of neurological symptoms (relapses) followed by periods of partial or complete recovery (remissions).
  evidence:
  - reference: PMID:25997994
    reference_title: "Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review."
    supports: SUPPORT
    snippet: Relapses (episodic exacerbations of neurological signs or symptoms) are a defining feature of relapsing-remitting multiple sclerosis (MS), the most prevalent MS phenotype.
    explanation: The abstract clearly states that relapses are a defining feature of relapsing-remitting MS, supporting the statement about periods of neurological symptoms followed by partial or complete recovery.
  - reference: PMID:34006674
    reference_title: "[Relapsing-Remitting Multiple Sclerosis]."
    supports: SUPPORT
    snippet: The relapsing-remitting type is a major clinical course in MS.
    explanation: This reference confirms that the relapsing-remitting type is a major clinical course in MS, aligning with the statement about periods of relapses and remissions.
  - reference: PMID:31971066
    reference_title: "Recovery of cognitive function after relapse in multiple sclerosis."
    supports: SUPPORT
    snippet: Cognitive impairment is common in multiple sclerosis (MS) but its manifestation as acute disease activity is underappreciated... In RG patients, SDMT declined from 55.2 to 44.6 at relapse and recovered to 51.7
    explanation: This study highlights cognitive function decline during relapses and subsequent recovery, supporting the characterization of MS by periods of neurological symptoms followed by recovery.
- phase: Secondary Progressive
  notes: Following an initial relapsing-remitting phase, there is a progressive worsening of neurological function over time.
  evidence:
  - reference: PMID:16545751
    reference_title: "Secondary progressive multiple sclerosis: current knowledge and future challenges."
    supports: SUPPORT
    snippet: The secondary progressive phase of multiple sclerosis (MS), which is characterised by a steady accrual of fixed disability after an initial relapsing remitting course, is not clearly understood.
    explanation: The reference describes secondary progressive MS as a phase that follows an initial relapsing-remitting course and is characterized by progressive worsening of neurological function.
  - reference: PMID:20946934
    reference_title: "Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis."
    supports: SUPPORT
    snippet: This transforms into a disease of continuous and irreversible neurological decline by the sixth or seventh decade.
    explanation: The reference supports the statement by describing the transition from an initial phase with reversible episodes to a phase of continuous and irreversible neurological decline.
  - reference: PMID:24722325
    reference_title: "Relapsing and progressive forms of multiple sclerosis: insights from pathology."
    supports: SUPPORT
    snippet: The predominant clinical disease course of multiple sclerosis starts with reversible episodes of neurological disability, which transforms into progressive neurological decline.
    explanation: The reference supports the statement by describing the progression from relapsing episodes to a phase of progressive neurological decline.
- phase: Primary Progressive
  notes: >-
    A gradual progression of disability from onset without early relapses and
    remissions. The 1996 clinical-course descriptors additionally recognized a
    "progressive-relapsing" (PRMS) phenotype; the 2013 revisions re-examined
    those categories and replaced them with descriptors qualified by disease
    activity and progression, so patients previously labelled PRMS are now
    classified as primary progressive MS with activity. PRMS is therefore not
    curated as a separate course.
  evidence:
  - reference: PMID:33578205
    reference_title: "Definitions of primary-progressive multiple sclerosis trajectories by rate of clinical disability progression."
    supports: SUPPORT
    snippet: Patients with primary progressive multiple sclerosis (PPMS) vary in the rate of disability progression.
    explanation: The statement describes a gradual progression of disability from onset without early relapses and remissions, which aligns with the characteristics of primary progressive MS (PPMS).
  - reference: PMID:35977131
    reference_title: "Multiple Sclerosis: A Primary Care Perspective."
    supports: SUPPORT
    snippet: Types of MS include relapsing-remitting (most common), secondary progressive, and primary progressive.
    explanation: This reference supports the classification of MS into types, including primary progressive MS, which is characterized by a gradual progression of disability from onset without early relapses and remissions.
  - reference: PMID:29157397
    reference_title: "Progressive Forms of Multiple Sclerosis: Distinct Entity or Age-Dependent Phenomena."
    supports: SUPPORT
    snippet: Subclinical activity in radiologically isolated syndrome evolving to primary-progressive MS is mostly indistinguishable from relapsing-remitting MS evolving to secondary-progressive MS.
    explanation: This reference supports the concept of primary progressive MS, which involves a gradual progression of disability without the early relapses and remissions seen in relapsing-remitting MS.
  - reference: PMID:24871874
    reference_title: "Defining the clinical course of multiple sclerosis: the 2013 revisions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Standardized descriptions published in 1996 based on a survey of
      international MS experts provided purely clinical phenotypes based on
      data and consensus at that time, but imaging and biological correlates
      were lacking.
    explanation: >-
      The International Advisory Committee re-examined the 1996 clinical-course
      phenotypes, which is the revision that retired the progressive-relapsing
      category.
  - reference: PMID:24871874
    reference_title: "Defining the clinical course of multiple sclerosis: the 2013 revisions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      we propose refined descriptors that include consideration of disease
      activity (based on clinical relapse rate and imaging findings) and
      disease progression
    explanation: >-
      Documents that the current descriptors qualify the progressive phenotypes
      by activity rather than retaining a separate progressive-relapsing course.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_autoimmune_demyelination_neurodegeneration_model
  hypothesis_label: Canonical Autoimmune Demyelination and Neurodegeneration Model
  status: CANONICAL
  description: >-
    In genetically susceptible individuals (HLA-DRB1*15:01 and >200 additional risk variants), autoreactive CD4+ Th1/Th17 and CD8+ T cells, B cells, and plasmablasts cross the blood-brain barrier and orchestrate focal inflammatory demyelination of CNS white-matter and gray-matter lesions. The resulting myelin loss is paralleled by progressive axonal and neuronal damage, with chronic active ("smoldering") inflammation and meningeal lymphoid aggregates driving disability accumulation in progressive MS. EBV infection of B cells is now established as a near-necessary upstream environmental trigger. Disease-modifying therapies that deplete B cells (anti-CD20), sequester lymphocytes in lymph nodes by blocking their egress (S1P receptor modulators such as fingolimod), or block alpha4-integrin (VLA-4)-mediated lymphocyte migration across the blood-brain barrier into the CNS (natalizumab) provide direct interventional validation of the autoimmune arm of the canonical model.
  notes: >-
    Retained as CANONICAL with significant qualifications.
    The 2026 openscientist hypothesis-search report
    (kb/hypotheses/Multiple_Sclerosis/canonical_autoimmune_demyelination_neurodegeneration_model)
    finds three foundational pillars robustly validated: (1) EBV
    infection as a near-necessary upstream trigger (32-fold MS risk
    increase, Bjornevik et al. 2022); (2) polygenic immune susceptibility
    (HLA-DRB1*15:01 + >200 GWAS loci enriched for adaptive immunity);
    (3) therapeutic proof-of-concept from anti-CD20 B-cell depletion,
    S1P modulators, and natalizumab (relapse reduction 46-70%, MRI
    activity >90% reduction). Critical qualification for progressive MS:
    disability accumulation is driven predominantly by **progression
    independent of relapse activity (PIRA)**, reflecting compartmentalized
    CNS inflammation, chronic active "smoldering" lesions, meningeal
    lymphoid follicles, and neurodegeneration that does not respond to
    peripheral B-cell depletion. Anti-CD20 in primary progressive MS
    has modest effect, signaling the need for CNS-penetrant strategies.
  evidence:
  - reference: PMID:24507511
    reference_title: "Immune regulation of multiple sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Multiple sclerosis (MS) is considered a prototype inflammatory autoimmune disorder of the central nervous system (CNS)"
    explanation: >
      Canonical mechanism review used as the seed reference for the
      hypothesis-search deep-research run.
  - reference: PMID:35025605
    reference_title: "Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Serum levels of neurofilament light chain, a biomarker of neuroaxonal degeneration, increased only after EBV seroconversion."
    explanation: >-
      Supports the ordering the notes assert, not just the association: in the
      >10 million-person military cohort the neuroaxonal-degeneration biomarker
      rose only after EBV seroconversion, placing the exposure upstream of
      measurable CNS injury. Surfaced by the 2026 OpenScientist run; the notes
      above had named this cohort without citing it.
  - reference: PMID:41284953
    reference_title: "Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying Treatments."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In all phenotypes, PIRA represented the main disability accrual mechanism."
    explanation: >-
      Substantiates the PIRA qualification in the notes above. Latent-class
      analysis of 2,563 untreated relapse-onset patients from the Italian MS
      Register found four disability-worsening phenotypes, with PIRA the main
      accrual mechanism in every one. Phenotypes were derived from EDSS alone,
      which the authors flag as a limitation.
  - reference: PMID:39711984
    reference_title: "Chronic active lesions in multiple sclerosis: classification, terminology, and clinical significance."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This condition, known as smoldering neuroinflammation, is present across the clinical spectrum of MS and is currently understood to be relatively resistant to treatment with existing disease-modifying therapies."
    explanation: >-
      Supports the notes' claim that the compartmentalized arm resists current
      peripheral disease-modifying therapy, which is the principal limit on the
      canonical model's therapeutic predictions. Review-level synthesis, hence
      OTHER. The OpenScientist report attributed this sentence to PMID:41961242;
      it is in fact from this paper (see the assessment sidecar).
- hypothesis_group_id: chronic_active_lesion_smouldering_inflammation_pira
  hypothesis_label: Compartmentalized Smouldering Chronic-Active-Lesion Inflammation Driving PIRA
  status: EMERGING
  description: >-
    A CNS-compartmentalized, innate-immune-driven mechanism proposes that
    disability accumulation in progressive MS is driven predominantly by
    progression independent of relapse activity (PIRA) rather than by acute
    peripheral-lymphocyte-mediated relapses. At the rim of chronic active
    ("smouldering") white-matter lesions — identifiable in vivo as iron-laden
    paramagnetic-rim lesions on MRI — a self-sustaining glial circuit maintains
    slow demyelination and axonal loss behind a relatively intact blood-brain
    barrier. Single-nucleus RNA-seq of the lesion edge (Absinta et al. 2021)
    defines disease-specific "microglia inflamed in MS" (MIMS) and "astrocytes
    inflamed in MS" states with neurodegenerative transcriptional programming,
    and implicates complement component 1q (C1q) as a critical upstream mediator
    of MIMS activation. Because this compartment sits behind the BBB, it is
    predicted to be refractory to peripheral B-cell depletion (consistent with
    the modest anti-CD20 effect in primary progressive MS) and to require
    CNS-penetrant, microglia/complement-directed strategies. The MIMS profile
    overlaps microglial states in other neurodegenerative diseases, suggesting a
    shared secondary-neurodegeneration mechanism.
  notes: >-
    Elevated from a qualification embedded in the CANONICAL model to its own
    EMERGING hypothesis because it makes distinct, testable predictions
    (BBB-compartmentalized innate/complement drive of PIRA; paramagnetic-rim
    lesions as a monitorable biomarker; CNS-penetrant complement/microglia
    targets) and is directly motivated by the single-nucleus dataset added to
    this entry (scea:E-GEOD-180759). An OpenScientist hypothesis-search
    deep-research run
    (kb/hypotheses/Multiple_Sclerosis/chronic_active_lesion_smouldering_inflammation_pira/)
    returned a PARTIALLY_SUPPORTED verdict, verified in the assessment sidecar
    (assessments/openscientist-assessment-by-claude-code.yaml; all load-bearing
    PMIDs confirmed real and quoted accurately). Well supported: the biomarker
    arm (paramagnetic-rim / slowly-expanding lesions predict PIRA) and the
    therapeutic / compartmentalization arm — the brain-penetrant BTK inhibitor
    tolebrutinib slows progression in non-relapsing SPMS (HERCULES phase 3,
    PMID:40202696) while peripheral anti-CD20 spares the astrocytic sGFAP marker
    and PIRMA (RIFUND-MS, PMID:41968564). Contested: the translation of the
    molecular core — C1q as an upstream driver of the MIMS state — from mouse
    EAE to human chronic active lesions. The seed study includes
    microglia-specific C1q ablation and therapeutic C1q blockade in mouse EAE,
    but longitudinal PPMS data associate elevated CSF C1q with lower progression
    risk (PMID:38912898), raising a compartment- and model-dependent
    interpretation question. Grey-matter and spinal-cord atrophy are a competing
    anatomical substrate for PIRA (PMID:41527428). Held at EMERGING pending
    independent human lesion-edge replication and evidence that the EAE C1q
    mechanism translates to human PIRA.
  evidence:
  - reference: PMID:34497421
    reference_title: "A lymphocyte-microglia-astrocyte axis in chronic active multiple sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We define 'microglia inflamed in MS' (MIMS) and 'astrocytes inflamed in MS', glial phenotypes that demonstrate neurodegenerative programming."
    explanation: >-
      Human single-nucleus RNA-seq defines the MIMS and inflamed-astrocyte states
      with neurodegenerative programming at the chronic active lesion edge.
  - reference: PMID:34497421
    reference_title: "A lymphocyte-microglia-astrocyte axis in chronic active multiple sclerosis."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We identify complement component 1q (C1q) as a critical mediator of MIMS activation, validated immunohistochemically in MS tissue, genetically by microglia-specific C1q ablation in mice with experimental autoimmune encephalomyelitis, and therapeutically by treating chronic experimental autoimmune encephalomyelitis with C1q blockade."
    explanation: >-
      Microglia-specific C1q ablation and therapeutic C1q blockade provide direct
      causal perturbation evidence in mouse EAE. Whether that mechanism operates
      in human chronic active lesions remains the translational gap.
  - reference: PMID:41205558
    reference_title: "Paramagnetic iron rim lesions as a prognostic factor for disability progression in multiple sclerosis: A systematic review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PRLs are associated with an increased risk of MS progression through PIRA."
    explanation: >-
      A systematic review of five studies and 744 patients supports paramagnetic
      rim lesions as prognostic imaging markers for PIRA and confirmed
      disability progression.
  - reference: PMID:40897401
    reference_title: "Diffusivity anisotropy signature of slowly expanding lesions predicts progression independent of relapse activity in multiple sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Definite SELs show distinct greater microstructural damage and are associated with PIRA, making their FA signature a potential predictor of MS progression."
    explanation: >-
      Sources the slowly-expanding-lesion half of the biomarker arm, which the
      notes above assert alongside paramagnetic rims but had cited only for
      rims. A prospective diffusion-MRI cohort of 130 patients followed a median
      9.2 years, of whom 29 (22%) developed PIRA, found progressive
      fractional-anisotropy decline in definite-SEL cores. Observational and
      single-centre, so it strengthens the association without establishing that
      lesion-rim biology causes the progression.
  - reference: PMID:41968564
    reference_title: "Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing-Remitting MS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The risk of progression independent of relapse and MRI activity (PIRMA) was higher with RTX (HR 3.3, CI 1.1-10, p = 0.04)."
    explanation: >-
      RIFUND-MS supports dissociation between peripheral B-cell depletion and
      non-inflammatory progression, consistent with a compartmentalized CNS
      process, while not proving a lesion-rim or C1q mechanism.
  - reference: PMID:40202696
    reference_title: "Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A smaller percentage of participants in the tolebrutinib group than in the placebo group had confirmed disability progression sustained for at least 6 months (22.6% vs. 30.7%; hazard ratio, 0.69; 95% confidence interval, 0.55 to 0.88; P = 0.003)."
    explanation: >-
      Phase 3 HERCULES trial: a CNS-penetrant, myeloid/microglia-directed BTK
      inhibitor slows relapse-independent progression in non-relapsing SPMS —
      the therapeutic prediction of the BBB-compartmentalized model. Surfaced and
      verified via the OpenScientist run. Does not by itself prove the benefit is
      mediated by lesion-rim microglia (no PRL-mediation analysis exists).
  - reference: PMID:38912898
    reference_title: "Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "increased CSF C1q levels predicted lower disability progression (adjusted OR 0.41; 95% CI 0.17-0.86; p = 0.025)"
    explanation: >-
      Complicates direct translation of the lesion-rim C1q mechanism: elevated
      bulk CSF C1q predicted lower disability progression in a longitudinal PPMS
      cohort. The different compartment and analyte do not directly refute local
      microglial C1q activity, but require a compartment-resolved interpretation.
pathophysiology:
- name: Demyelination
  description: The immune system attacks and destroys myelin, the protective sheath around nerve fibers, disrupting nerve signal transmission.
  downstream:
  - target: Neurological Disability
    description: Autoimmune demyelination and neuronal loss lead to progressive neurological disability.
    evidence:
    - reference: PMID:40636815
      reference_title: "Multiple sclerosis: 2024 update."
      supports: SUPPORT
      snippet: Multiple sclerosis (MS) is a complex immune-mediated disease that leads to neurological disability
      explanation: This 2024 review explicitly states the causal relationship between the immune-mediated (autoimmune) nature of MS and neurological disability.
  cell_types:
  - preferred_term: Oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: Microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  - preferred_term: CD4-positive, alpha-beta T cell
    term:
      id: CL:0000624
      label: CD4-positive, alpha-beta T cell
  biological_processes:
  - preferred_term: Antigen processing and presentation of peptide antigen via MHC class II
    term:
      id: GO:0002495
      label: antigen processing and presentation of peptide antigen via MHC class II
  - preferred_term: T cell activation
    term:
      id: GO:0042110
      label: T cell activation
  - preferred_term: Cytokine-mediated signaling pathway
    term:
      id: GO:0019221
      label: cytokine-mediated signaling pathway
  - preferred_term: Complement activation
    term:
      id: GO:0006956
      label: complement activation
  - preferred_term: Myelination
    term:
      id: GO:0042552
      label: myelination
  locations:
  - preferred_term: Central nervous system
    term:
      id: UBERON:0001017
      label: central nervous system
  - preferred_term: Meninges
    term:
      id: UBERON:0002360
      label: meninx
  - preferred_term: White matter
    term:
      id: UBERON:0002316
      label: white matter
  - preferred_term: Gray matter
    term:
      id: UBERON:0002020
      label: gray matter
  - preferred_term: Brain
    term:
      id: UBERON:0000955
      label: brain
  - preferred_term: Spinal cord
    term:
      id: UBERON:0002240
      label: spinal cord
  evidence:
  - reference: PMID:24507511
    reference_title: "Immune regulation of multiple sclerosis."
    supports: SUPPORT
    snippet: Multiple sclerosis (MS) is considered a prototype inflammatory autoimmune disorder of the central nervous system (CNS)... These autoreactive lymphocytes can migrate to the CNS where they become reactivated upon encountering their target antigen, initiating an autoimmune inflammatory attack. This ultimately leads to demyelination and axonal damage.
    explanation: The literature supports that MS involves the immune system attacking myelin in the CNS, leading to demyelination. It specifically mentions the role of autoreactive lymphocytes, which include T and B lymphocytes.
  - reference: PMID:19847447
    reference_title: "Oligodendrocytes: biology and pathology."
    supports: SUPPORT
    snippet: Oligodendrocytes are the myelinating cells of the central nervous system (CNS)... we will lay out the different pathways leading to oligodendrocyte and myelin loss in human CNS diseases...
    explanation: The literature supports the involvement of oligodendrocytes in myelination and their loss in CNS diseases like MS, which leads to demyelination.
  - reference: PMID:36889543
    reference_title: "Schwann Cell Remyelination in the Multiple Sclerosis Central Nervous System."
    supports: SUPPORT
    snippet: Multiple sclerosis (MS) is a central nervous system (CNS) demyelinating disease... CNS myelin is normally produced by oligodendroglial cells.
    explanation: The literature supports that MS is a demyelinating disease affecting the CNS, with oligodendrocytes being the cells responsible for myelin production.
  - reference: PMID:37629092
    reference_title: "Alterations of Oligodendrocyte and Myelin Energy Metabolism in Multiple Sclerosis."
    supports: SUPPORT
    snippet: Multiple sclerosis (MS) is a complex autoimmune disease of the central nervous system (CNS), characterized by demyelination and neurodegeneration. Oligodendrocytes play a vital role in maintaining the integrity of myelin... However, in MS, oligodendrocytes become dysfunctional, leading to myelin damage and axonal degeneration.
    explanation: The literature supports that MS involves demyelination and neurodegeneration in the CNS, with oligodendrocytes playing a crucial role in this process.
  - reference: PMID:15727225
    reference_title: "Lessons from the neuropathology of atypical forms of multiple sclerosis."
    supports: SUPPORT
    snippet: Multiple sclerosis (MS) is characterized by multiple demyelinated inflammatory lesions disseminated in the central nervous system (CNS)... different mechanisms of demyelination, such as T-cell/macrophage-mediated demyelination, antibody/complement-mediated demyelination, and primary damage of the oligodendrocyte have been observed in individual MS patients.
    explanation: The literature supports that MS involves demyelination in the CNS and mentions the role of T-cells and oligodendrocytes in this process.
  - reference: PMID:21425268
    reference_title: "Targeting oligodendrocyte protection and remyelination in multiple sclerosis."
    supports: SUPPORT
    snippet: Multiple sclerosis is an inflammatory demyelinating disease of the brain and spinal cord with a presumed autoimmune etiology... Approaches that directly protect myelin-producing oligodendrocytes and enhance remyelination may improve long-term outcomes...
    explanation: The literature supports that MS is an autoimmune disease causing demyelination in the CNS, involving oligodendrocytes.
  - reference: PMID:28674983
    reference_title: "Multiple Sclerosis: Basic and Clinical."
    supports: SUPPORT
    snippet: MS is a chronic inflammatory disease of the central nervous system caused by aberrant immune activation resulting in damage to myelin sheaths within the brain and spinal cord and axonal loss
    explanation: The literature supports that MS involves immune activation leading to damage of myelin sheaths in the CNS.
  - reference: PMID:17548563
    reference_title: "Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis."
    supports: SUPPORT
    snippet: Substantial evidence supports autoimmune activity as the etiologic mechanism underlying multiple sclerosis (MS)... Both the innate and the adaptive arms of the immune system are involved in the aberrant response to several antigens associated with the myelin sheath and oligodendrocytes (OGCs)...
    explanation: The literature supports that MS is an autoimmune disease involving the immune system's attack on myelin and oligodendrocytes in the CNS.
  - reference: PMID:24507514
    reference_title: "Demyelination in multiple sclerosis."
    supports: SUPPORT
    snippet: This review, focused on demyelination in multiple sclerosis, is divided in two parts. The first part addresses the many and not exclusive mechanisms leading to demyelination in the central nervous system... the influence of a primary immune response against myelin antigen(s), with a diversity of potential targets.
    explanation: The literature supports that MS involves immune responses against myelin antigens leading to demyelination in the CNS.
- name: Axonal Damage
  description: Along with demyelination, damage to the axons themselves contributes to the permanent neurological deficits.
  evidence:
  - reference: PMID:21425267
    reference_title: "Axonal damage in multiple sclerosis."
    supports: SUPPORT
    snippet: Here, we review distinct, but not mutually exclusive, mechanisms of pathogenesis of axonal damage in multiple sclerosis patients that are either consequent to long-term demyelination or independent from it.
    explanation: The article discusses axonal damage as a significant factor in the pathogenesis of multiple sclerosis, supporting the statement that axonal damage contributes to permanent neurological deficits.
  - reference: PMID:17115075
    reference_title: "Axonal conduction and injury in multiple sclerosis: the role of sodium channels."
    supports: SUPPORT
    snippet: Recent studies have implicated specific sodium channel isoforms as having an important role in several aspects of the pathophysiology of MS, including the restoration of impulse conduction after demyelination, axonal degeneration and the mistuning of Purkinje neurons that leads to cerebellar dysfunction.
    explanation: The article mentions axonal degeneration as part of the pathophysiology of MS, supporting the statement that axonal damage contributes to permanent neurological deficits.
  - reference: PMID:25159125
    reference_title: "Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability?"
    supports: SUPPORT
    snippet: Axonal degeneration is a major determinant of permanent neurological impairment during multiple sclerosis (MS).
    explanation: The article directly states that axonal degeneration is a major determinant of permanent neurological impairment in MS, which supports the statement.
  - reference: PMID:25159125
    reference_title: "Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability?"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "when this energy demand exceeds axonal ATP production, it may undergo hypoxic-like axonal degeneration"
    explanation: >
      Full-text mechanistic finding: demyelination raises axonal energy demand,
      and when this exceeds ATP production the axon undergoes hypoxic-like
      (virtual hypoxia) degeneration, mechanistically linking demyelination and
      mitochondrial energy failure to the axonal damage that drives permanent
      deficits. Tagged OTHER as a mechanistic review synthesis.
  - reference: PMID:31760649
    reference_title: "Roads to Formation of Normal Myelin Structure and Pathological Myelin Structure."
    supports: SUPPORT
    snippet: Demyelination and axonal damage are responsible for neurological deficits in demyelinating diseases including multiple sclerosis (MS), an inflammatory demyelinating disease of the central nervous system.
    explanation: The article explicitly mentions that both demyelination and axonal damage are responsible for neurological deficits in MS, supporting the statement.
  - reference: PMID:17884680
    reference_title: "Primary-progressive multiple sclerosis."
    supports: SUPPORT
    snippet: Although neuroaxonal degeneration seems to underlie PPMS, the pathogenesis and the extent to which immune-mediated mechanisms operate is unclear.
    explanation: The article discusses neuroaxonal degeneration as underlying primary-progressive multiple sclerosis (PPMS), which supports the statement.
- name: EBNA1-GlialCAM Molecular Mimicry
  biological_scale: MOLECULAR
  description: >-
    Antibodies raised against the Epstein-Barr virus nuclear antigen 1 (EBNA1)
    cross-react with the CNS protein glial cell adhesion molecule (GlialCAM),
    supplying a molecular route from EBV infection of B cells to a CNS-directed
    adaptive response. The cross-reactivity was found in clonally expanded
    cerebrospinal-fluid B cells of people with MS and is structurally resolved
    at the EBNA1 AA386-405 epitope; anti-EBNA1 and anti-GlialCAM responses are
    elevated in MS and interact with the HLA-DRB1*15:01 risk allele. Whether
    this mimicry is sufficient to initiate disease, or one of several routes
    (bystander activation, immortalization of autoreactive B cells) is
    unresolved.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: Cerebrospinal-fluid plasmablast
    term:
      id: CL:0000980
      label: plasmablast
  biological_processes:
  - preferred_term: B cell activation
    term:
      id: GO:0042113
      label: B cell activation
  - preferred_term: Humoral immune response mediated by circulating immunoglobulin
    term:
      id: GO:0002455
      label: humoral immune response mediated by circulating immunoglobulin
  locations:
  - preferred_term: Central nervous system
    term:
      id: UBERON:0001017
      label: central nervous system
  downstream:
  - target: Inflammatory Lesions
    description: >-
      Cross-reactive anti-EBNA1 immunity is proposed to feed the CNS-directed
      autoimmune attack that produces focal inflammatory lesions. The causal
      step is currently carried by a model system: immunizing against EBNA1
      worsens experimental autoimmune encephalomyelitis.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35073561
      reference_title: "Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "EBNA1 immunization exacerbates disease in a mouse model of MS"
      explanation: >-
        Perturbation evidence for the edge, in a mouse model rather than in
        humans: raising anti-EBNA1 immunity exacerbates CNS autoimmune disease.
        It does not establish that the mimicry initiates human lesion formation.
  evidence:
  - reference: PMID:35073561
    reference_title: "Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Here we demonstrate high-affinity molecular mimicry between the EBV transcription factor EBV nuclear antigen 1 (EBNA1) and the central nervous system protein glial cell adhesion molecule (GlialCAM)"
    explanation: >-
      Establishes the mimicry itself. Cross-reactivity was identified by
      single-cell sequencing of the paired-chain B-cell repertoire of MS blood
      and CSF and then characterized by protein microarray, affinity
      measurement, and a crystal structure of the EBNA1 epitope bound to the
      autoreactive Fab - biochemical and structural assays outside an organism,
      hence IN_VITRO.
  - reference: PMID:40063790
    reference_title: "Antibody reactivity against EBNA1 and GlialCAM differentiates multiple sclerosis patients from healthy controls."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Blocking experiments confirmed the presence of cross-reactive antibodies and molecular mimicry between EBNA1 and GlialCAM, and accompanying antibody responses against adjacent peptide regions of GlialCAM suggest epitope spreading."
    explanation: >-
      Independent confirmation in 650 MS patients versus 661 matched population
      controls. Note the authors write that spreading to adjacent GlialCAM
      regions is suggested, not demonstrated; the OpenScientist report that
      surfaced this paper overstated that verb.
  - reference: PMID:40063790
    reference_title: "Antibody reactivity against EBNA1 and GlialCAM differentiates multiple sclerosis patients from healthy controls."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Antibody responses against EBNA1, GlialCAM, CRYAB, and ANO2 are elevated in MS patients carrying the main risk allele HLA-DRB1*15:01"
    explanation: >-
      Ties the mimicry response to the entry's principal genetic risk factor:
      the cross-reactive antibody responses are elevated in HLA-DRB1*15:01
      carriers, and the combination raises MS risk additively.
- name: Th1/Th17-Mediated Neuroinflammation
  description: MS immunopathology is mediated by myelin-reactive CD4+ T cells of Th1 and Th17 lineage. Th17 cells produce IL-17, IL-22, and other proinflammatory cytokines that disrupt blood-brain barrier tight junction proteins and recruit neutrophils into the CNS. The IL-23/IL-17 axis amplifies neuroinflammation.
  biological_processes:
  - preferred_term: T-helper 17 type immune response
    term:
      id: GO:0072538
      label: T-helper 17 type immune response
  - preferred_term: Inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  cell_types:
  - preferred_term: T-helper 17 cell
    term:
      id: CL:0000899
      label: T-helper 17 cell
  - preferred_term: T-helper 1 cell
    term:
      id: CL:0000545
      label: T-helper 1 cell
  genes:
  - preferred_term: HLA-DRB1
    term:
      id: hgnc:4948
      label: HLA-DRB1
  - preferred_term: TYK2
    term:
      id: hgnc:12440
      label: TYK2
  - preferred_term: STAT3
    term:
      id: hgnc:11364
      label: STAT3
  - preferred_term: IL7R
    term:
      id: hgnc:6024
      label: IL7R
  - preferred_term: IL2RA
    term:
      id: hgnc:6008
      label: IL2RA
  - preferred_term: CD40
    term:
      id: hgnc:11919
      label: CD40
  - preferred_term: CD28
    term:
      id: hgnc:1653
      label: CD28
  downstream:
  - target: Inflammatory Lesions
    description: Autoreactive Th17 cells migrate through the BBB and drive focal demyelinating lesion formation.
  - target: Oligodendrocyte Precursor and Microglial Autophagic-Mitophagic Dysregulation
    description: >-
      The proinflammatory cytokine milieu generated by Th1/Th17 cells is one
      of the inducers used to establish the in vitro and in vivo MS models in
      which autophagic-mitophagic flux is dysregulated.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:34099564
      reference_title: "Antipsychotic drugs counteract autophagy and mitophagy in multiple sclerosis."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "in vitro and in vivo MS models (induced by proinflammatory cytokines, lysolecithin, and cuprizone) are associated with strongly impaired mitochondrial activity, inducing a lactic acid metabolism and prompting an increase in the autophagic flux and in mitophagy"
      explanation: >-
        States that proinflammatory-cytokine induction is one of the routes
        used to generate the models in which autophagic/mitophagic flux is
        dysregulated, naming this specific edge. Graded OTHER rather than
        MODEL_ORGANISM or IN_VITRO because the sentence covers both the in
        vitro and in vivo model arms together and cannot be cleanly split.
  evidence:
  - reference: PMID:32801039
    reference_title: "The role of TH17 cells in multiple sclerosis: Therapeutic implications."
    supports: SUPPORT
    snippet: Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) where immunopathology is thought to be mediated by myelin-reactive CD4+ T helper (TH) cells. The TH cells most commonly implicated in the pathogenesis of the disease are of TH1 and TH17 lineage, which are defined by the production of interferon-γ and interleukin-17, respectively.
    explanation: Directly establishes TH1 and TH17 cells as the key drivers of MS immunopathology.
  - reference: PMID:21338381
    reference_title: "Th17 cell, the new player of neuroinflammatory process in multiple sclerosis."
    supports: SUPPORT
    snippet: Multiple sclerosis (MS) is an autoimmune disease characterized by recurrent episodes of demyelination and axonal lesion mediated by CD4(+) T cells with a proinflammatory Th1 and Th17 phenotype, macrophages, and soluble inflammatory mediators.
    explanation: Confirms Th1 and Th17 phenotypes as mediators of MS demyelination and axonal damage.
  - reference: PMID:21338381
    reference_title: "Th17 cell, the new player of neuroinflammatory process in multiple sclerosis."
    supports: SUPPORT
    snippet: Autoreactive Th17 cells can migrate through the BBB by the production of cytokines such as IL-17 and IL-22, which disrupt tight junction proteins in the central nervous system (CNS) endothelial cells.
    explanation: Describes the mechanism by which Th17 cells cross the BBB via IL-17 and IL-22 disruption of tight junctions.
- name: Inflammatory Lesions
  description: Immune cells crossing the blood-brain barrier create focal areas of inflammation in the central nervous system.
  biological_processes:
  - preferred_term: Inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  cell_types:
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  genes:
  - preferred_term: TNFRSF1A
    term:
      id: hgnc:11916
      label: TNFRSF1A
  evidence:
  - reference: PMID:21550344
    reference_title: "How do immune cells overcome the blood-brain barrier in multiple sclerosis?"
    supports: SUPPORT
    snippet: Leukocyte entry into the CNS is nonetheless an early event in multiple sclerosis (MS), an inflammatory disorder of the CNS... Immune cells of MS subjects express inflammatory cytokines, reactive oxygen species (ROS) and enzymes that can facilitate their migration to the CNS by influencing BBB function, either directly or indirectly.
    explanation: This reference supports the statement that immune cells cross the blood-brain barrier and create inflammation in the central nervous system.
  - reference: PMID:34440810
    reference_title: "What Guides Peripheral Immune Cells into the Central Nervous System?"
    supports: SUPPORT
    snippet: During this early stage of the disease, leukocytes cross the blood-brain barrier to drive the formation of focal demyelinating plaques.
    explanation: This reference directly supports the statement by mentioning that leukocytes cross the blood-brain barrier and drive the formation of focal demyelinating plaques, which are inflammatory lesions.
  - reference: PMID:30407467
    reference_title: "[Actualidades en la inmunopatología de la esclerosis múltiple]."
    supports: SUPPORT
    snippet: Neuroinflammation is triggered when peripheral leukocytes migrate to the central nervous system and release cytokines such as interleukins 1 and 6 (IL-1 and 6) and tumor necrosis factor (TNF), which act on dwelling cells.
    explanation: This reference supports the statement by explaining that peripheral leukocytes migrate to the CNS and trigger neuroinflammation.
  - reference: PMID:29515568
    reference_title: "The Role of Astrocytes in Multiple Sclerosis."
    supports: SUPPORT
    snippet: Astrocytes are now recognized to be early and highly active players during lesion formation and key for providing peripheral immune cells access to the central nervous system.
    explanation: This reference supports the statement by mentioning the role of astrocytes in providing access for peripheral immune cells to the CNS, contributing to lesion formation.
- name: Compartmentalized CNS Inflammation
  description: >
    Chronic inflammation behind a relatively closed blood-brain barrier,
    including chronic active lesions, meningeal inflammation, and innate immune
    activation, contributes to smoldering tissue injury and disability
    progression not fully captured by conventional relapse-focused MRI outcomes.
  biological_processes:
  - preferred_term: Inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  cell_types:
  - preferred_term: Microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  locations:
  - preferred_term: Meninges
    term:
      id: UBERON:0002360
      label: meninx
  - preferred_term: Gray matter
    term:
      id: UBERON:0002020
      label: gray matter
  downstream:
  - target: Axonal Damage
    description: >-
      Persistent compartmentalized inflammation at chronic active lesion rims
      sustains demyelination and axonal degeneration that contribute to PIRA.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - chronic active lesion demyelination
    hypothesis_groups:
    - chronic_active_lesion_smouldering_inflammation_pira
  - target: Microglial NLRP3 Inflammasome Activation
    description: >-
      Innate immune activation within chronic active lesions provides the
      priming and myelin-debris danger signals that drive NLRP3 inflammasome
      assembly in lesion-resident microglia.
  - target: Chronic Inflammation-Induced Oligodendroglial and Glial Senescence
    description: >-
      Soluble factors released by pro-inflammatory microglia within
      compartmentalized lesions drive a senescent phenotype in nearby
      oligodendrocyte-lineage cells.
    evidence:
    - reference: PMID:38722375
      reference_title: "Physiological aging and inflammation-induced cellular senescence may contribute to oligodendroglial dysfunction in MS."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Impaired differentiation and upregulation of cellular senescence markers could be induced in young dchiOL in vitro using supernatants from pro-inflammatory microglia."
      explanation: >-
        Directly shows that soluble factors from pro-inflammatory microglia are
        sufficient to induce cellular-senescence markers and impair maturation
        in human oligodendrocyte-lineage cells, establishing this specific
        inflammation-to-senescence edge rather than only the two node-level
        claims.
  evidence:
  - reference: DOI:10.1177/13524585241301303
    reference_title: Imaging Outcomes for Phase 2 Trials Targeting Compartmentalized Inflammation
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      This review discusses several emerging imaging technologies that could be
      used as surrogate markers of compartmentalized inflammation, targeting
      chronic active lesions, meningeal inflammation, and innate immune
      activation within the normal-appearing white matter and gray matter.
    explanation: >
      The deep-research review highlighted compartmentalized inflammation as a
      key mechanism of progression; this abstract supports the asserted lesion,
      meningeal, microglial/innate, and gray-matter compartments.
  - reference: PMID:34293193
    reference_title: "Ectopic lymphoid follicles in progressive multiple sclerosis: From patients to animal models."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ELFs can be found in the meninges of around 40% of the investigated progressive multiple sclerosis (MS) post-mortem brain tissues and are associated with the severity of cortical degeneration and clinical disease progression."
    explanation: >-
      Sources the meningeal compartment specifically, which the node and the
      canonical hypothesis both assert. Ectopic lymphoid follicles occur in
      roughly 40% of progressive-MS post-mortem brains and track cortical
      degeneration severity and clinical progression. Carry the 40% as an
      approximate post-mortem prevalence: the same review notes that the
      absence of a uniform ELF definition impedes reproducible comparison
      across neuropathology series.
- name: Oligodendrocyte Precursor and Microglial Autophagic-Mitophagic Dysregulation
  conforms_to: "disabled_macroautophagy#Failure of Cytoplasmic Quality Control"
  biological_scale: CELLULAR
  description: >-
    Autophagic and mitophagic flux is dysregulated in MS lesions: microglial
    autophagy declines with age and disease-associated activation, impairing
    phagocytic clearance of myelin debris, while autophagy and mitophagy marker
    levels rise in patients' biofluids during active disease and in
    demyelinating models, where the resulting autophagic flux itself
    contributes to impaired mitochondrial function and defective myelin
    production. The pathway's core ATG-mediated cytoplasmic quality-control
    function is lost either way, so this node conforms to the disabled
    macroautophagy hallmark-of-aging module rather than asserting a single
    direction of dysregulation.
  cell_types:
  - preferred_term: Microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: Oligodendrocyte precursor cell
    term:
      id: CL:0002453
      label: oligodendrocyte precursor cell
  biological_processes:
  - preferred_term: Macroautophagy
    modifier: DYSREGULATED
    term:
      id: GO:0016236
      label: macroautophagy
  - preferred_term: Mitophagy
    modifier: INCREASED
    term:
      id: GO:0000422
      label: autophagy of mitochondrion
  genes:
  - preferred_term: BECN1
    term:
      id: hgnc:1034
      label: BECN1
  downstream:
  - target: Demyelination
    description: >-
      Structurally and mechanistically unrelated autophagy inhibitors improve
      myelin production and normalize axonal myelination in demyelinating
      models, indicating that the dysregulated autophagic-mitophagic flux
      itself impairs myelin maintenance rather than merely accompanying it.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:34099564
      reference_title: "Antipsychotic drugs counteract autophagy and mitophagy in multiple sclerosis."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Multiple structurally and mechanistically unrelated inhibitors of autophagy improved myelin production and normalized axonal myelination"
      explanation: >-
        Independent autophagy inhibitors reversing the myelin/mitochondrial
        defect in cytokine-, lysolecithin-, and cuprizone-induced MS models
        supports a causal (not merely correlative) role for excess autophagic
        flux in impairing myelination.
  evidence:
  - reference: PMID:34099564
    reference_title: "Antipsychotic drugs counteract autophagy and mitophagy in multiple sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the levels of autophagy and mitophagy markers are significantly increased in the biofluids of MS patients during the active phase of the disease, indicating activation of these processes"
    explanation: >-
      Primary human biofluid evidence that autophagy and mitophagy are
      dysregulated specifically during active-phase MS, distinct from the
      review (PMID:42419491) that first raised this axis as a hypothesis.
  - reference: PMID:34099564
    reference_title: "Antipsychotic drugs counteract autophagy and mitophagy in multiple sclerosis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "in vitro and in vivo MS models (induced by proinflammatory cytokines, lysolecithin, and cuprizone) are associated with strongly impaired mitochondrial activity, inducing a lactic acid metabolism and prompting an increase in the autophagic flux and in mitophagy"
    explanation: >-
      Shows that impaired mitochondrial activity in MS models drives increased
      autophagic/mitophagic flux, mechanistically linking the two processes.
      Graded OTHER because the quoted sentence covers both the in vitro and
      in vivo model arms in one clause and cannot be cleanly split into
      single-source items.
  - reference: PMID:38363533
    reference_title: "Autophagy in Multiple Sclerosis: Phagocytosis and Autophagy of Oligodendrocyte Precursor Cells."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "further changes in these autophagy genes were verified in the experimental autoimmune encephalomyelitis (EAE) model and oligodendrocyte precursor cells (OPCs) engulfed myelin debris (MD)"
    explanation: >-
      Confirms altered expression of autophagy-related genes specifically in
      OPCs engulfing myelin debris in the EAE model of MS.
  - reference: PMID:38363533
    reference_title: "Autophagy in Multiple Sclerosis: Phagocytosis and Autophagy of Oligodendrocyte Precursor Cells."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Becn1 showed obvious expression abnormalities suggesting that this gene has vital functions in autophagy and MD engulfed by OPCs"
    explanation: >-
      Identifies BECN1 (Beclin-1), a core macroautophagy gene, as specifically
      dysregulated in OPCs during myelin-debris engulfment.
- name: Chronic Inflammation-Induced Oligodendroglial and Glial Senescence
  conforms_to: "cellular_senescence#Senescent Cell Accumulation"
  biological_scale: CELLULAR
  description: >-
    p16INK4a+ and 53BP1+ senescent cells accumulate within actively
    demyelinating white- and gray-matter lesions, with co-localization to
    oligodendrocytes, astrocytes, microglia, macrophages, and neurons.
    Senescence-associated secretory phenotype (SASP) factors are elevated in
    the CSF of affected patients, and a higher senescent-cell burden is
    associated with faster disability progression. Inflammation-induced
    senescence markers can also be induced in human oligodendrocyte-lineage
    cells directly by pro-inflammatory microglial secretions.
  cell_types:
  - preferred_term: Oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  - preferred_term: Microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  biological_processes:
  - preferred_term: Cellular senescence
    modifier: INCREASED
    term:
      id: GO:0090398
      label: cellular senescence
  locations:
  - preferred_term: White matter
    term:
      id: UBERON:0002316
      label: white matter
  - preferred_term: Gray matter
    term:
      id: UBERON:0002020
      label: gray matter
  downstream:
  - target: Demyelination
    description: >-
      A greater senescent-cell load in demyelinated lesions is associated with
      faster loss of ambulation and earlier death, consistent with the
      persistent SASP secretome impairing remyelination capacity and
      sustaining lesion pathology.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - senescence-associated secretory phenotype
    evidence:
    - reference: PMID:39891488
      reference_title: "Accelerated Cellular Senescence in Progressive Multiple Sclerosis: A Histopathological Study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "P16+ cell counts in WMLs exhibited an inverse correlation with time to requiring a wheelchair and with age at death."
      explanation: >-
        Directly links senescent-cell burden within white-matter lesions to
        the pace of disability accumulation, an outcome captured elsewhere in
        this entry's `phenotypes` and `progression` sections.
  evidence:
  - reference: PMID:39891488
    reference_title: "Accelerated Cellular Senescence in Progressive Multiple Sclerosis: A Histopathological Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "P16+ cell counts were significantly increased in WMLs and GMLs, compared with NAWM, CWM, NAGM, and CGM and lipofuscin+ cells were significantly increased in WMLs, compared with NAWM and CWM, indicating more abundant CS in demyelinated lesions."
    explanation: >-
      Primary post-mortem histopathology directly demonstrating senescent-cell
      accumulation specifically within demyelinated MS lesions.
  - reference: PMID:39891488
    reference_title: "Accelerated Cellular Senescence in Progressive Multiple Sclerosis: A Histopathological Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Co-localization studies showed evidence of CS in neurons, astrocytes, oligodendrocytes, microglia, and macrophages."
    explanation: >-
      Establishes which lesion-resident cell types carry senescence markers.
  - reference: PMID:38722375
    reference_title: "Physiological aging and inflammation-induced cellular senescence may contribute to oligodendroglial dysfunction in MS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we observed an accelerated epigenetic aging of the myelinated, normal appearing white matter of multiple sclerosis (MS) patients compared to healthy individuals"
    explanation: >-
      Independent human-tissue evidence of accelerated cellular/epigenetic
      aging specifically in MS white matter.
- name: Microglial NLRP3 Inflammasome Activation
  conforms_to: "nlrp3_inflammasome_activation#NLRP3 Inflammasome Assembly and Caspase-1 Activation"
  biological_scale: MOLECULAR
  description: >-
    NLRP3, PYCARD (ASC), CASP1, IL1B, and IL18 transcripts are elevated
    specifically within chronic active lesions in progressive MS, and NLRP3
    inflammasome activity (NLRP3-dependent IL-1beta release; NLRP3, IL1B, and
    GSDMD expression) is elevated in circulating immune cells from people with
    MS relative to healthy controls, indicating dysregulated NLRP3
    inflammasome assembly both centrally and peripherally.
  cell_types:
  - preferred_term: Microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  biological_processes:
  - preferred_term: NLRP3 inflammasome complex assembly
    modifier: INCREASED
    term:
      id: GO:0044546
      label: NLRP3 inflammasome complex assembly
  genes:
  - preferred_term: NLRP3
    term:
      id: hgnc:16400
      label: NLRP3
  - preferred_term: PYCARD
    term:
      id: hgnc:16608
      label: PYCARD
  - preferred_term: CASP1
    term:
      id: hgnc:1499
      label: CASP1
  locations:
  - preferred_term: White matter
    term:
      id: UBERON:0002316
      label: white matter
  downstream:
  - target: Axonal Damage
    description: >-
      NLRP3-dependent IL-1beta/IL-18 maturation and gasdermin-D-associated
      pyroptotic signaling within chronic active lesions add a further,
      innate-immune route to the tissue injury that manifests as axonal
      damage.
  evidence:
  - reference: PMID:41687275
    reference_title: "Elevated expression of the NLRP3 inflammasome in post-mortem brain white matter and immune cells in multiple sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The expression of NLRP3, IL1B, IL18, CASP1 and PYCARD transcripts were elevated in chronic active lesions (CALs) in PPMS cases, with no significant alterations determined in SPMS CNS tissue."
    explanation: >-
      Primary post-mortem brain evidence localizing NLRP3 inflammasome pathway
      upregulation specifically to chronic active lesions in progressive MS.
  - reference: PMID:41687275
    reference_title: "Elevated expression of the NLRP3 inflammasome in post-mortem brain white matter and immune cells in multiple sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "NLRP3-dependent IL-1β release, alongside NLRP3, IL1B and GSDMD expression, were significantly elevated in immune cells isolated from pwMS (primarily RRMS), when compared to PBMCs from healthy controls."
    explanation: >-
      Independent evidence of NLRP3-dependent IL-1beta release and gasdermin-D
      (pyroptosis effector) expression in peripheral immune cells from people
      with MS.
phenotypes:
- category: Neurologic
  name: Muscle Weakness
  frequency: FREQUENT
  evidence:
  - reference: PMID:35977131
    reference_title: "Multiple Sclerosis: A Primary Care Perspective."
    supports: SUPPORT
    snippet: "Common symptoms include sensory disturbances, motor weakness, impaired gait, incoordination, optic neuritis, and Lhermitte sign"
    explanation: This primary-care review lists motor weakness among the common symptoms of MS, directly supporting muscle weakness as a frequent manifestation.
  - reference: PMID:26863109
    reference_title: "Disability and Fatigue Can Be Objectively Measured in Multiple Sclerosis."
    supports: SUPPORT
    snippet: Hip mROM was extremely sensitive in measuring lower limb motor impairment, being correlated with muscle strength and also altered in patients without clinically detectable disability.
    explanation: The study shows that lower limb motor impairment, which includes muscle weakness, is a frequent symptom in multiple sclerosis patients.
  - reference: PMID:15228757
    reference_title: "Central nervous system atrophy and clinical status in multiple sclerosis."
    supports: SUPPORT
    snippet: Cross-sectional studies have demonstrated a moderate but significant correlation between brain or spinal cord atrophy and physical disability in patients with MS.
    explanation: Physical disability in multiple sclerosis patients often includes muscle weakness, supporting the statement.
  phenotype_term:
    preferred_term: Muscle weakness
    term:
      id: HP:0001324
      label: Muscle weakness
- category: Neurologic
  name: Vision Problems
  frequency: FREQUENT
  notes: Including optic neuritis and double vision.
  evidence:
  - reference: PMID:15664543
    reference_title: "The neuro-ophthalmology of multiple sclerosis."
    supports: SUPPORT
    snippet: The commonness of visual sensory and eye movement abnormalities in MS highlights the importance of understanding the principles addressed in this review.
    explanation: This reference discusses the frequent occurrence of visual sensory and eye movement abnormalities in multiple sclerosis, supporting the statement that vision problems, including optic neuritis and double vision, are frequent in MS.
  - reference: PMID:32981685
    reference_title: "Vision Problems in Multiple Sclerosis."
    supports: SUPPORT
    snippet: Vision Problems in Multiple Sclerosis.
    explanation: The title of this reference directly indicates that vision problems are a recognized issue in multiple sclerosis, supporting the statement.
  - reference: PMID:34939452
    reference_title: "Ocular manifestations of multiple sclerosis in patients from three countries: A Web-based survey."
    supports: SUPPORT
    snippet: The first ocular crisis or clinical debut of MS is characterized by slow and progressive visual impairment, increasing and adding to other ocular manifestations during its evolutionary course.
    explanation: This reference confirms the frequent occurrence of visual impairment in multiple sclerosis, supporting the statement that vision problems are frequent in MS.
- category: Neurologic
  name: Fatigue
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:3355400
    reference_title: "Fatigue in multiple sclerosis."
    supports: SUPPORT
    snippet: Fatigue is a frequent symptom in multiple sclerosis (MS) that can interfere with a patient's daily functioning.
    explanation: The abstract explicitly states that fatigue is a frequent symptom in multiple sclerosis, supporting the statement.
  - reference: PMID:26195047
    reference_title: "Relation of quantitative visual and neurologic outcomes to fatigue in multiple sclerosis."
    supports: SUPPORT
    snippet: The relation of fatigue in multiple sclerosis (MS) to the visual system, an emerging structural and functional surrogate in MS, has not been well established.
    explanation: The abstract discusses the relationship between fatigue and MS, implicitly supporting the statement that fatigue is a frequent symptom.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Neurologic
  name: Gait and Balance Issues
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Gait disturbance
    term:
      id: HP:0001288
      label: Gait disturbance
  evidence:
  - reference: PMID:30482317
    reference_title: "Balance, gait, and falls in multiple sclerosis."
    supports: SUPPORT
    snippet: MS is characterized by clinical symptoms resulting from lesions in the brain, spinal cord, or optic nerves that can affect balance, gait, and fall risk.
    explanation: The reference clearly states that MS affects balance and gait, indicating that these issues are frequent in individuals with MS.
  - reference: PMID:38141562
    reference_title: "Smartphone-based gait assessment for multiple sclerosis."
    supports: SUPPORT
    snippet: Multiple Sclerosis causes gait alteration, even in the early stages of the disease.
    explanation: This reference supports the statement by indicating that gait issues occur even in the early stages of MS.
  - reference: PMID:35174869
    reference_title: "Intensive Circuit Class Therapy in Patients with Relapsing-Remitting Multiple Sclerosis."
    supports: SUPPORT
    snippet: Intensive circuit class therapy is an effective therapeutic approach for improving gait and balance problems in patients with MS.
    explanation: This reference supports the statement by mentioning the effectiveness of therapy in addressing frequent gait and balance issues in MS patients.
- category: Neurologic
  name: Spasticity
  frequency: FREQUENT
  evidence:
  - reference: PMID:22721362
    reference_title: "[Editorial. Spasticity in multiple sclerosis]."
    supports: SUPPORT
    snippet: Spasticity in multiple sclerosis
    explanation: The title of the article directly mentions spasticity in the context of multiple sclerosis.
  - reference: PMID:30286958
    reference_title: "Common Etiologies of Upper Extremity Spasticity."
    supports: SUPPORT
    snippet: The most common causes leading to spasticity include stroke, traumatic brain injury, multiple sclerosis, spinal cord injury, and cerebral palsy.
    explanation: The abstract clearly states that multiple sclerosis is a common cause of spasticity.
  - reference: PMID:32120056
    reference_title: "Ghost spasticity in multiple sclerosis."
    supports: SUPPORT
    snippet: Spasticity is the velocity-dependent hypertonia frequently encountered in patients affected by Upper Motor Neuron Syndrome.
    explanation: The abstract discusses spasticity in the context of multiple sclerosis, indicating it is a frequent symptom.
  - reference: PMID:10101582
    reference_title: "Spasticity, ataxia and fatigue in multiple sclerosis."
    supports: SUPPORT
    snippet: Chief among these symptoms, both in relation to their frequency and their impact on the patient, are spasticity, ataxia and fatigue.
    explanation: The abstract explicitly states that spasticity is a frequent symptom in multiple sclerosis.
  - reference: PMID:22612755
    reference_title: "Management of spasticity in progressive multiple sclerosis: efficacy of repeated intrathecal triamcinolone acetonide administration."
    supports: SUPPORT
    snippet: Spasticity is one of the most common symptoms.
    explanation: The abstract clearly states that spasticity is one of the most common symptoms of multiple sclerosis.
  - reference: PMID:20586738
    reference_title: "Clinical assessment and management of spasticity: a review."
    supports: SUPPORT
    snippet: Spasticity is a sign of upper motor neurone lesion, which can be located in the cerebrum or the spinal cord, and be caused by stroke, multiple sclerosis, spinal cord injury, brain injury, cerebral paresis, or other neurological conditions.
    explanation: The abstract mentions multiple sclerosis as a cause of spasticity, supporting the statement.
  - reference: PMID:26611270
    reference_title: "Country break-out session highlights."
    supports: SUPPORT
    snippet: Individuals with multiple sclerosis (MS) spasticity present a wide range of symptoms and disability levels that are frequently challenging to manage.
    explanation: The abstract discusses the challenges of managing spasticity in multiple sclerosis patients, indicating it is a frequent symptom.
  - reference: PMID:30626509
    reference_title: "Special Considerations and Assessment in Patients with Multiple Sclerosis."
    supports: SUPPORT
    snippet: Spasticity in patients with multiple sclerosis can be debilitating and detrimental to the function and quality of life of patients.
    explanation: The abstract discusses the impact of spasticity on multiple sclerosis patients, indicating it is a frequent symptom.
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
- category: Neurologic
  name: Cognitive Impairment
  frequency: FREQUENT
  notes: Difficulties with memory, attention, and information processing.
  evidence:
  - reference: PMID:37379870
    reference_title: "Cognitive impairment in multiple sclerosis: \"classic\" knowledge and recent acquisitions."
    supports: SUPPORT
    snippet: Multiple sclerosis causes motor, sensory, cerebellar, and autonomic dysfunctions, as well as cognitive and psychoemotional impairment. The most frequently compromised cognitive domains are complex attention/information processing, memory, executive and visuospatial functions.
    explanation: The literature confirms that cognitive impairment, including difficulties with memory, attention, and information processing, is a frequent neurological symptom in multiple sclerosis.
  - reference: PMID:27207446
    reference_title: "Information processing speed in multiple sclerosis: Past, present, and future."
    supports: SUPPORT
    snippet: Information processing speed (IPS) is a prevalent cognitive impairment in multiple sclerosis (MS).
    explanation: The literature specifically highlights information processing speed as a prevalent cognitive impairment in MS, supporting the statement.
  - reference: PMID:37031630
    reference_title: "Do cardiovascular disease comorbidities affect the cognitive function of Multiple Sclerosis patients?"
    supports: SUPPORT
    snippet: Cognitive impairment is a core symptom of multiple sclerosis, leading to disability in 40-70% of patients. The most common cognitive domains affected by MS are information processing speed, complex attention, executive functions and less frequently, episodic declarative memory.
    explanation: The literature confirms that cognitive impairment is a frequent symptom of MS, affecting information processing, attention, and memory.
  phenotype_term:
    preferred_term: Cognitive Impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
- category: Neurologic
  name: Bladder and Bowel Dysfunction
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Neurogenic bladder
    term:
      id: HP:0000011
      label: Neurogenic bladder
  evidence:
  - reference: PMID:7707085
    reference_title: "Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction."
    supports: SUPPORT
    snippet: Urinary dysfunction is common in cases of multiple sclerosis (MS)... A total of 52% currently had at least one bowel symptom.
    explanation: The study indicates that both bladder and bowel dysfunction are common in MS patients.
  - reference: PMID:37084150
    reference_title: "Autonomic nervous system disorders in multiple sclerosis."
    supports: SUPPORT
    snippet: Manifestations of MS in the ANS include urological, sexual, gastrointestinal, cardiovascular, and thermoregulatory disorders...
    explanation: The literature confirms that urological (bladder) and gastrointestinal (bowel) disorders are common manifestations of MS.
  - reference: PMID:20955903
    reference_title: "Review of neurologic diseases for the urologist."
    supports: SUPPORT
    snippet: This article reviews the neurologic conditions associated with a high prevalence of bladder dysfunction...
    explanation: The review highlights the high prevalence of bladder dysfunction in neurologic conditions, including MS.
  - reference: PMID:24314685
    reference_title: "Bladder management in multiple sclerosis."
    supports: SUPPORT
    snippet: This article reviews the basic principles and therapeutic options in the management of the neurogenic bladder due to multiple sclerosis (MS)...
    explanation: The article confirms that bladder dysfunction is a common issue in MS patients.
- category: Neurologic
  name: Sensory Disturbances
  frequency: FREQUENT
  notes: Numbness and reduced sensation in limbs (hypoesthesia).
  phenotype_term:
    preferred_term: Hypoesthesia
    term:
      id: HP:0033748
      label: Hypoesthesia
  evidence:
  - reference: PMID:2602337
    reference_title: "Weakness, numbness, tingling and multiple sclerosis."
    supports: SUPPORT
    snippet: Multiple sclerosis is the most common serious neurological disease in young patients but it is not the only cause of paraesthesiae. Such sensory symptoms occur frequently and reflect a variety of underlying conditions.
    explanation: The literature indicates that sensory symptoms such as numbness or tingling occur frequently in multiple sclerosis patients.
  - reference: PMID:33296981
    reference_title: "A longitudinal study of symptom botheration in Multiple Sclerosis."
    supports: SUPPORT
    snippet: Small but significant increases during followup were seen in dexterity, bladder, vision, and pain domains, while significant decreases were seen in anxiety and sensory domains.
    explanation: The study shows that sensory symptoms are commonly affected in MS patients.
  - reference: PMID:38795594
    reference_title: "Relationship between sensation and balance and gait in multiple sclerosis patients with mild disability."
    supports: SUPPORT
    snippet: Patients with Multiple Sclerosis (PwMS) often experience sensory, balance, and gait problems.
    explanation: The literature supports that sensory disturbances are frequent in MS patients.
  - reference: PMID:10554672
    reference_title: "Sensory-motor and genito-sphincter dysfunctions in multiple sclerosis."
    supports: SUPPORT
    snippet: Among the symptoms, sensory-motor disorders and genito-sphincter dysfunctions are some of the more disabling.
    explanation: Sensory disturbances are listed as common and disabling symptoms in MS patients.
  - reference: PMID:10408718
    reference_title: "Sensory symptoms of multiple sclerosis: a hidden reservoir of morbidity."
    supports: SUPPORT
    snippet: Sensory symptoms were more common in MS patients than in controls, and differed in severity and quality.
    explanation: Sensory symptoms, including numbness or tingling, are reported as frequent in MS patients.
- category: Neurologic
  name: Ataxia
  frequency: FREQUENT
  notes: Lack of voluntary coordination of muscle movements; cerebellar dysfunction
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
- category: Neurologic
  name: Optic Neuritis
  frequency: FREQUENT
  notes: Inflammation of the optic nerve causing visual impairment or loss
  phenotype_term:
    preferred_term: Optic neuritis
    term:
      id: HP:0100653
      label: Optic neuritis
- category: Neurologic
  name: Dysesthesia
  frequency: FREQUENT
  notes: Abnormal unpleasant sensations such as burning or prickling
  phenotype_term:
    preferred_term: Dysesthesia
    term:
      id: HP:0012534
      label: Dysesthesia
- category: Neurologic
  name: Pain
  frequency: VERY_FREQUENT
  notes: >
    Overall pain prevalence is 63% in MS. Includes neuropathic extremity pain (26%),
    headache (43%), back pain (20%), painful spasms (15%), and trigeminal neuralgia (4%).
  phenotype_term:
    preferred_term: Pain
    term:
      id: HP:0012531
      label: Pain
  evidence:
  - reference: PMID:23318126
    reference_title: "Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis."
    supports: SUPPORT
    snippet: "Pooled overall pain prevalence (17 studies, 5319 subjects) was 63%"
    explanation: Meta-analysis of 28 articles (7101 subjects) establishes overall pain prevalence at 63% in MS.
  - reference: PMID:23318126
    reference_title: "Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis."
    supports: SUPPORT
    snippet: "neuropathic extremity pain (26%"
    explanation: Provides detailed prevalence estimates for specific pain subtypes in MS.
- category: Neuropsychiatric
  name: Depression
  frequency: FREQUENT
  notes: >
    Pooled prevalence of depression is 30.5%, with clinically significant depressive
    symptoms in 35% of patients. Common comorbidity that significantly impacts quality of life.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: PMID:28017241
    reference_title: "Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis."
    supports: SUPPORT
    snippet: "Pooled mean prevalence was 30.5% (95% CI=26.3%-35.1%) for depression, and 22.1% (95% CI=15.2%-31.0%) for anxiety"
    explanation: Large meta-analysis of 58 articles (87,756 MS patients) establishes depression prevalence at 30.5% in MS.
- category: Neurologic
  name: Intention Tremor
  frequency: FREQUENT
  notes: >
    Predominantly large-amplitude postural and kinetic tremor, most commonly affecting
    the arms. Linked to cerebellar pathology and suggests more aggressive disease course.
  phenotype_term:
    preferred_term: Intention tremor
    term:
      id: HP:0002080
      label: Intention tremor
  evidence:
  - reference: PMID:23439953
    reference_title: "Understanding tremor in multiple sclerosis: prevalence, pathological anatomy, and pharmacological and surgical approaches to treatment."
    supports: SUPPORT
    snippet: "tremor is one of the most prevalent and disabling features of multiple sclerosis (MS)"
    explanation: Review establishes tremor as a prevalent and disabling feature of MS.
  - reference: PMID:23439953
    reference_title: "Understanding tremor in multiple sclerosis: prevalence, pathological anatomy, and pharmacological and surgical approaches to treatment."
    supports: SUPPORT
    snippet: "The predominant type of MS tremor is a large-amplitude, postural, and kinetic tremor, which most commonly affects the arms"
    explanation: Characterizes the predominant tremor type in MS as large-amplitude postural and kinetic tremor.
- category: Neurologic
  name: Lhermitte Sign
  frequency: FREQUENT
  notes: >
    Electric shock-like sensation radiating down the spine upon neck flexion.
    Prevalence 16-41% in MS, correlates with cervical MRI abnormalities.
  phenotype_term:
    preferred_term: Lhermitte's sign
    term:
      id: HP:0032504
      label: Lhermitte's sign
  evidence:
  - reference: PMID:16042221
    reference_title: "Reappraisal of Lhermitte's sign in multiple sclerosis."
    supports: SUPPORT
    snippet: "Forty-one per cent of the patients and none of the controls reported having LS during the course of their illness"
    explanation: Study of 300 MS patients found 41% prevalence of Lhermitte's sign.
  - reference: PMID:23318126
    reference_title: "Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis."
    supports: SUPPORT
    snippet: "Lhermitte sign (16%"
    explanation: Meta-analysis estimates Lhermitte sign prevalence at 16% in MS.
- category: Neurologic
  name: Nystagmus
  frequency: FREQUENT
  notes: Involuntary rhythmic eye movements, often of cerebellar or brainstem origin
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  evidence:
  - reference: PMID:15664543
    reference_title: "The neuro-ophthalmology of multiple sclerosis."
    supports: SUPPORT
    snippet: "The commonness of visual sensory and eye movement abnormalities in MS highlights the importance of understanding the principles addressed in this review"
    explanation: Review of neuro-ophthalmology in MS confirms eye movement abnormalities including nystagmus are common.
- category: Neurologic
  name: Diplopia
  frequency: FREQUENT
  notes: Double vision resulting from brainstem lesions affecting oculomotor pathways
  phenotype_term:
    preferred_term: Diplopia
    term:
      id: HP:0000651
      label: Diplopia
  evidence:
  - reference: PMID:15664543
    reference_title: "The neuro-ophthalmology of multiple sclerosis."
    supports: SUPPORT
    snippet: "inflammatory demyelination can involve more eloquent sites, such as the optic nerve and brainstem"
    explanation: Brainstem demyelination in MS produces oculomotor dysfunction including diplopia.
- category: Neurologic
  name: Dysphagia
  frequency: FREQUENT
  notes: >
    Swallowing difficulty affecting approximately 45% of MS patients.
    Prevalence increases with disease progression and disability.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:36630841
    reference_title: "Prevalence of dysphagia in patients with multiple sclerosis: A systematic review and meta-analysis."
    supports: SUPPORT
    snippet: "The overall prevalence of dysphagia across all 54 studies was 44.8 %"
    explanation: Large meta-analysis of 54 studies (11,266 MS cases) establishes dysphagia prevalence at 45% in MS.
- category: Neurologic
  name: Vertigo
  frequency: FREQUENT
  notes: Sensation of spinning or dizziness, often due to brainstem or cerebellar lesions
  phenotype_term:
    preferred_term: Vertigo
    term:
      id: HP:0002321
      label: Vertigo
  evidence:
  - reference: PMID:25877451
    reference_title: "Substantial burden of dizziness in multiple sclerosis."
    supports: SUPPORT
    snippet: "Dizziness affects 49-59% of persons with MS"
    explanation: Large registry study (8123 participants) establishes high prevalence of dizziness/vertigo in MS.
  - reference: PMID:25877451
    reference_title: "Substantial burden of dizziness in multiple sclerosis."
    supports: SUPPORT
    snippet: "Dizziness is common in MS and adversely impacts quality of life"
    explanation: Confirms dizziness/vertigo as a common MS symptom with significant impact on quality of life.
- category: Neurologic
  name: Paresthesia
  frequency: VERY_FREQUENT
  notes: Tingling, pins-and-needles sensations; often an early presenting symptom
  phenotype_term:
    preferred_term: Paresthesia
    term:
      id: HP:0003401
      label: Paresthesia
  evidence:
  - reference: PMID:2602337
    reference_title: "Weakness, numbness, tingling and multiple sclerosis."
    supports: SUPPORT
    snippet: "Multiple sclerosis is the most common serious neurological disease in young patients but it is not the only cause of paraesthesiae. Such sensory symptoms occur frequently"
    explanation: Confirms that paresthesia (paraesthesiae) occurs frequently in MS and is a common presenting symptom.
  - reference: PMID:35977131
    reference_title: "Multiple Sclerosis: A Primary Care Perspective."
    supports: SUPPORT
    snippet: "Common symptoms include sensory disturbances, motor weakness, impaired gait, incoordination, optic neuritis, and Lhermitte sign"
    explanation: Sensory disturbances including paresthesia are listed as common symptoms of MS.
- category: Genitourinary
  name: Male Sexual Dysfunction
  frequency: FREQUENT
  notes: >
    Pooled prevalence of 63% in men with MS. Includes erectile dysfunction,
    decreased libido, and orgasmic dysfunction.
  phenotype_term:
    preferred_term: Male sexual dysfunction
    term:
      id: HP:0040307
      label: Male sexual dysfunction
  evidence:
  - reference: PMID:33407874
    reference_title: "Prevalence of sexual dysfunction in men with multiple sclerosis: a systematic review and meta-analysis."
    supports: SUPPORT
    snippet: "the pooled prevalence of sexual dysfunction in men with MS in all studies was 62.9% with a 95% confidence interval 53 to 72.7%"
    explanation: Meta-analysis of 20 studies establishes high prevalence of sexual dysfunction (62.9%) in men with MS.
- name: "Internuclear ophthalmoplegia"
  category: Neurologic
  description: "Medial longitudinal fasciculus demyelination produces internuclear ophthalmoplegia, a frequent ocular-motor sign of MS."
  phenotype_term:
    preferred_term: "Internuclear ophthalmoplegia"
    term:
      id: HP:0030773
      label: "Internuclear ophthalmoplegia"
  evidence:
  - reference: PMID:34348598
    reference_title: "Disorders of vision in multiple sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "internuclear ophthalmoplegia, with failure of ipsilateral eye adduction and contralateral eye abduction nystagmus"
    explanation: "This review attributes internuclear ophthalmoplegia in MS to medial longitudinal fasciculus lesions."
- name: "Memory impairment"
  category: Neurologic
  description: "Memory impairment is a cognitive manifestation of multiple sclerosis linked to hippocampal involvement."
  phenotype_term:
    preferred_term: "Memory impairment"
    term:
      id: HP:0002354
      label: "Memory impairment"
  evidence:
  - reference: PMID:30264730
    reference_title: "The hippocampus in multiple sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "clinical manifestations of multiple sclerosis, such as memory impairment and depression"
    explanation: "This review attributes memory impairment in MS partly to hippocampal involvement."
biochemical:
- name: Oligoclonal Bands
  presence: Positive
  context: Detected in cerebrospinal fluid during lumbar puncture.
  evidence:
  - reference: PMID:31031747
    reference_title: "The Cerebrospinal Fluid in Multiple Sclerosis."
    supports: SUPPORT
    snippet: The hallmark of MS-specific changes in CSF is the detection of oligoclonal bands (OCB) which occur in the vast majority of MS patients.
    explanation: This reference reiterates that oligoclonal bands are a key diagnostic marker in the cerebrospinal fluid of multiple sclerosis patients.
  - reference: PMID:32408148
    reference_title: "From Baló's concentric sclerosis to multiple sclerosis: a series of 6 patients."
    supports: SUPPORT
    snippet: Oligoclonal bands were identified in 5/6 patients. After 7 years of follow-up, all patients achieved MS criteria with mild disability
    explanation: This reference shows that oligoclonal bands were detected in the cerebrospinal fluid of patients who later met the criteria for multiple sclerosis.
  - reference: PMID:29452342
    reference_title: "Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome."
    supports: SUPPORT
    snippet: Neurofilament light chain levels and oligoclonal bands were independent risk factors for the development of clinically isolated syndrome (hazard ratio = 1.02, P = 0.019, and hazard ratio = 14.7, P = 0.012, respectively) and multiple sclerosis
    explanation: This reference indicates that oligoclonal bands are present in the cerebrospinal fluid and are a risk factor for the development of multiple sclerosis.
imaging_findings:
- name: Multifocal periventricular white matter lesions on MRI
  modality: MRI
  imaging_finding_term:
    preferred_term: Multifocal cerebral white matter lesions
    term:
      id: HP:0007052
      label: Multifocal cerebral white matter abnormalities
  located_in:
    preferred_term: brain white matter
    term:
      id: UBERON:0003544
      label: brain white matter
  spatial_extent: MULTIFOCAL
  phenotype_term:
    preferred_term: Multifocal cerebral white matter abnormalities
    term:
      id: HP:0007052
      label: Multifocal cerebral white matter abnormalities
  diagnostic: true
  notes: >-
    T2/FLAIR-hyperintense demyelinating lesions with a periventricular,
    juxtacortical, infratentorial, and spinal-cord distribution. Dissemination
    in space (lesions in characteristic CNS regions) is a core McDonald
    diagnostic criterion.
  evidence:
  - reference: PMID:29275977
    reference_title: "Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: symptomatic lesions can be used to demonstrate dissemination in space or time in patients with supratentorial, infratentorial, or spinal cord syndrome
    explanation: The 2017 McDonald criteria establish that CNS lesions demonstrating dissemination in space are a core diagnostic criterion for multiple sclerosis.
  - reference: PMID:33780808
    reference_title: "Low-field portable brain MRI in CNS demyelinating disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These images demonstrate the ability to identify a solitary demyelinating lesion in early stage disease and cortical atrophy and chronic white matter changes in late stage disease.
    explanation: MRI identifies demyelinating white matter lesions characteristic of MS across disease stages.
- name: Gadolinium-enhancing lesion
  modality: MRI
  imaging_finding_term:
    preferred_term: Gadolinium-enhancing demyelinating lesion
  located_in:
    preferred_term: brain white matter
    term:
      id: UBERON:0003544
      label: brain white matter
  diagnostic: true
  notes: >-
    Contrast enhancement marks blood-brain-barrier breakdown at sites of active
    inflammatory demyelination. Simultaneous enhancing and non-enhancing lesions
    demonstrate dissemination in time. This finding carries no dedicated NCIT/HP
    term, so it is left to preferred_term (binding is RECOMMENDED, not required).
  evidence:
  - reference: PMID:32388832
    reference_title: "Gadolinium enhancement on cranial MRI in multiple sclerosis is age dependent."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Gadolinium-enhancing lesions are a biomarker of inflammatory disease activity in MS
    explanation: Gadolinium enhancement identifies active inflammatory demyelinating lesions on MRI.
diagnosis:
- name: MRI with Gadolinium Contrast
  presence: Positive
  notes: Used to identify areas of demyelination in the brain and spinal cord.
  evidence:
  - reference: PMID:25909791
    reference_title: "[Contrast agents in MRI-diagnosis of multiple sclerosis]."
    supports: SUPPORT
    snippet: Magnetic resonance imaging using contrast agents plays an important role in diagnosis and assessment of treatment efficacy in multiple sclerosis.
    explanation: The use of MRI with gadolinium contrast is highlighted as important for diagnosing and assessing treatment efficacy in multiple sclerosis, which involves identifying areas of demyelination.
  - reference: PMID:33872085
    reference_title: "Multiple sclerosis: prevalence of the 'central vein' sign in white matter lesions on gadolinium-enhanced susceptibility-weighted images."
    supports: SUPPORT
    snippet: Gadolinium-enhanced susceptibility-weighted imaging improves the detection rate of the central vein sign in multiple sclerosis lesions.
    explanation: This study demonstrates that gadolinium-enhanced MRI improves the detection of specific signs in multiple sclerosis lesions, which are related to demyelination.
  - reference: PMID:32388832
    reference_title: "Gadolinium enhancement on cranial MRI in multiple sclerosis is age dependent."
    supports: SUPPORT
    snippet: Gadolinium-enhancing lesions are a biomarker of inflammatory disease activity in MS
    explanation: Gadolinium-enhancing lesions are used as a biomarker for inflammatory activity in MS, indicating areas of active demyelination.
  - reference: PMID:33780808
    reference_title: "Low-field portable brain MRI in CNS demyelinating disease."
    supports: SUPPORT
    snippet: These images demonstrate the ability to identify a solitary demyelinating lesion in early stage disease and cortical atrophy and chronic white matter changes in late stage disease.
    explanation: The use of MRI, including with gadolinium contrast, is shown to identify demyelinating lesions and other changes in the brain associated with multiple sclerosis.
  - reference: PMID:33901207
    reference_title: "Blood-brain barrier breakdown in non-enhancing multiple sclerosis lesions detected by 7-Tesla MP2RAGE ΔT1 mapping."
    supports: SUPPORT
    snippet: Measurement of the changes in T1 relaxation time caused by contrast on 7T MP2RAGE reveals clinically relevant evidence of BBB breakdown in NELs in MS.
    explanation: The study discusses how gadolinium contrast in MRI can reveal blood-brain barrier breakdown in multiple sclerosis lesions, which is associated with demyelination.
- name: Lumbar Puncture
  presence: Presence of oligoclonal bands in cerebrospinal fluid.
  evidence:
  - reference: PMID:35662071
    reference_title: "Repeated lumbar puncture in search of oligoclonal bands - What is the yield?"
    supports: SUPPORT
    snippet: Cerebrospinal fluid (CSF) oligoclonal bands (OCBs) are immunoglobulins that represent intrathecal synthesis during central nervous system infection or inflammation.
    explanation: This study confirms that the presence of oligoclonal bands in cerebrospinal fluid is relevant in the context of central nervous system conditions, including multiple sclerosis.
  - reference: PMID:38791450
    reference_title: "Multiple Sclerosis: From the Application of Oligoclonal Bands to Novel Potential Biomarkers."
    supports: SUPPORT
    snippet: Current diagnosis is based on the integration of clinical, imaging, and laboratory results, with the latter based on the presence of intrathecal IgG oligoclonal bands in the cerebrospinal fluid whose detection via isoelectric focusing followed by immunoblotting represents the gold standard.
    explanation: This study highlights that oligoclonal bands in cerebrospinal fluid are a gold standard in the laboratory diagnosis of multiple sclerosis.
  - reference: PMID:15557527
    reference_title: "CSF characteristics in early-onset multiple sclerosis."
    supports: SUPPORT
    snippet: CSF oligoclonal IgG supports the early diagnosis of MS in childhood with a sensitivity similar to adult-onset MS.
    explanation: The presence of oligoclonal bands in cerebrospinal fluid is noted to support the diagnosis of multiple sclerosis in both early-onset and adult-onset cases.
  - reference: PMID:29571849
    reference_title: "Oligoclonal bands and periventricular lesions in multiple sclerosis will not increase blood-brain barrier permeability."
    supports: SUPPORT
    snippet: OB and PVLs were associated each other, but they did not affect the clinical course or increased the BBB-permeability within MS patients.
    explanation: This study indicates that oligoclonal bands are associated with multiple sclerosis, although they do not necessarily affect the clinical course or blood-brain barrier permeability.
- name: Evoked Potentials
  presence: Delayed response times.
  notes: Tests that measure the electrical activity in the brain in response to stimuli.
  evidence:
  - reference: PMID:24314688
    reference_title: "Evoked potentials in multiple sclerosis."
    supports: SUPPORT
    snippet: The identification of an area of the central nervous system showing abnormal conduction was used to supplement the abnormal signs identified on the physical examination-thus identifying the "multiple" in MS.
    explanation: The reference discusses the use of evoked potentials to identify areas of abnormal conduction in the CNS, which supports the statement about delayed response times in MS.
  - reference: PMID:35963325
    reference_title: "Transcranial direct current stimulation as a preventive treatment in multiple sclerosis? Preclinical evidence."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Optic nerve demyelination, associated with delay of visual evoked potentials (VEPs), is also observed prior to motor signs in the preclinical MS model Experimental Autoimmune Encephalomyelitis (EAE).
    explanation: Links optic nerve demyelination to delayed visual evoked potentials, but in the EAE animal model rather than in patients; supports the rationale for evoked potentials without being human evidence.
  - reference: PMID:8610486
    reference_title: "Tests of autonomic dysfunction in patients with multiple sclerosis."
    supports: SUPPORT
    snippet: The sensitivity of SSR and RRIV is high and compatible with that of visual and somatosensory evoked potentials.
    explanation: This reference discusses the use of various evoked potentials in MS and their sensitivity, implying the presence of delayed responses.
  - reference: PMID:7698890
    reference_title: "Serial evoked potentials in multiple sclerosis bouts. Relation to steroid treatment."
    supports: SUPPORT
    snippet: Evoked potentials may be useful for monitoring acute Multiple Sclerosis bouts and evaluating the effect of therapy.
    explanation: This reference supports the use of evoked potentials in monitoring MS, which implies the presence of delayed responses as part of the evaluation.
genetic:
- name: HLA-DRB1
  gene_term:
    preferred_term: HLA-DRB1
    term:
      id: hgnc:4948
      label: HLA-DRB1
  association: Risk Factor
  notes: Notably DRB1*15:01 allele; strongest genetic risk factor for MS
  evidence:
  - reference: PMID:28676141
    reference_title: "HLA-DRB1*15 association with multiple sclerosis is confirmed in a multigenerational Italian family."
    supports: SUPPORT
    snippet: HLA-DRB1*15 association with multiple sclerosis is confirmed in a multigenerational Italian family.
    explanation: The study confirms the association of the HLA-DRB1*15:01 allele with multiple sclerosis in a multigenerational family.
  - reference: PMID:27802296
    reference_title: "A Risk Score for Predicting Multiple Sclerosis."
    supports: SUPPORT
    snippet: Multiple sclerosis (MS) develops as a result of environmental influences on the genetically susceptible... Odds ratios for MS associated with each risk factor were derived from existing literature, and the log values of the odds ratios from each of the risk factors were combined in an additive model to provide an overall score.
    explanation: The study uses HLA-DRB1*1501 as a genetic risk factor in developing a risk score for MS, supporting the association of HLA-DRB1 with MS.
  - reference: PMID:21310812
    reference_title: "Genome-wide association studies in multiple sclerosis: lessons and future prospects."
    supports: SUPPORT
    snippet: A haplotype within the major histocompatibility region is the major risk factor for MS...
    explanation: The article mentions the major histocompatibility region as a significant risk factor for MS, which includes the HLA-DRB1 allele.
  - reference: PMID:25502788
    reference_title: "The Role of HLA in MS Susceptibility and Phenotype."
    supports: SUPPORT
    snippet: One of the most consistent findings in multiple sclerosis (MS) is that development of MS is linked with carriage of the class II human leucocyte antigen (HLA) molecule HLA-DRB1*15:01; around 60 % of Caucasian MS patients carry this allele compared to 25-30 % of ethnically matched healthy individuals.
    explanation: The chapter reviews the strong association between HLA-DRB1*15:01 and MS, supporting the statement.
- name: IL7R
  gene_term:
    preferred_term: IL7R
    term:
      id: hgnc:6024
      label: IL7R
  association: Risk Factor
  notes: Interleukin 7 receptor; involved in T cell homeostasis and immune regulation
  evidence:
  - reference: PMID:17660530
    reference_title: "Risk alleles for multiple sclerosis identified by a genomewide study."
    supports: SUPPORT
    snippet: Alleles of IL2RA and IL7RA and those in the HLA locus are identified as heritable risk factors for multiple sclerosis
    explanation: The first large-scale GWAS of multiple sclerosis identified IL7RA as a genome-wide significant susceptibility locus (P=2.94x10-7), establishing it as a heritable genetic risk factor for MS.
- name: IL2RA
  gene_term:
    preferred_term: IL2RA
    term:
      id: hgnc:6008
      label: IL2RA
  association: Risk Factor
  notes: Interleukin 2 receptor alpha chain; role in immune cell regulation
  evidence:
  - reference: PMID:17660530
    reference_title: "Risk alleles for multiple sclerosis identified by a genomewide study."
    supports: SUPPORT
    snippet: Alleles of IL2RA and IL7RA and those in the HLA locus are identified as heritable risk factors for multiple sclerosis
    explanation: The first large-scale GWAS of multiple sclerosis identified IL2RA as a genome-wide significant susceptibility locus (P=2.96x10-8), establishing it as a heritable genetic risk factor for MS.
- name: TYK2
  gene_term:
    preferred_term: TYK2
    term:
      id: hgnc:12440
      label: TYK2
  association: Risk Factor
  notes: Tyrosine kinase 2; involved in cytokine signaling pathways
- name: CD40
  gene_term:
    preferred_term: CD40
    term:
      id: hgnc:11919
      label: CD40
  association: Risk Factor
  notes: Costimulatory molecule on antigen presenting cells; involved in T and B cell interactions
- name: TNFRSF1A
  gene_term:
    preferred_term: TNFRSF1A
    term:
      id: hgnc:11916
      label: TNFRSF1A
  association: Risk Factor
  notes: TNF receptor superfamily member 1A; mediates inflammatory responses
- name: BACH2
  gene_term:
    preferred_term: BACH2
    term:
      id: hgnc:14078
      label: BACH2
  association: GWAS
  notes: Transcription factor regulating Treg/effector T cell balance and B cell class switching
- name: TNFAIP3
  gene_term:
    preferred_term: TNFAIP3
    term:
      id: hgnc:11896
      label: TNFAIP3
  association: GWAS
  notes: Encodes A20, a ubiquitin-editing enzyme that negatively regulates NF-kB signaling
- name: STAT3
  gene_term:
    preferred_term: STAT3
    term:
      id: hgnc:11364
      label: STAT3
  association: GWAS
  notes: Signal transducer mediating Th17 differentiation via JAK-STAT pathway
- name: IL10
  gene_term:
    preferred_term: IL10
    term:
      id: hgnc:5962
      label: IL10
  association: GWAS
  notes: Anti-inflammatory cytokine critical for immune tolerance
- name: CD28
  gene_term:
    preferred_term: CD28
    term:
      id: hgnc:1653
      label: CD28
  association: GWAS
  notes: T cell co-stimulatory receptor required for T cell activation
- name: EGR2
  gene_term:
    preferred_term: EGR2
    term:
      id: hgnc:3239
      label: EGR2
  association: GWAS
  notes: Transcription factor involved in T cell anergy and peripheral tolerance
- name: ETS1
  gene_term:
    preferred_term: ETS1
    term:
      id: hgnc:3488
      label: ETS1
  association: GWAS
  notes: Transcription factor regulating T and B cell development and immune cell differentiation
- name: IRF8
  gene_term:
    preferred_term: IRF8
    term:
      id: hgnc:5358
      label: IRF8
  association: GWAS
  notes: Interferon regulatory factor controlling myeloid cell development and type I interferon response
- name: SATB1
  gene_term:
    preferred_term: SATB1
    term:
      id: hgnc:10541
      label: SATB1
  association: GWAS
  notes: Chromatin organizer regulating T cell development and lineage commitment
- name: IKZF1
  gene_term:
    preferred_term: IKZF1
    term:
      id: hgnc:13176
      label: IKZF1
  association: GWAS
  notes: Ikaros transcription factor essential for lymphocyte development and differentiation
- name: REL
  gene_term:
    preferred_term: REL
    term:
      id: hgnc:9954
      label: REL
  association: GWAS
  notes: NF-kB subunit c-Rel controlling lymphocyte activation and survival
- name: PTPN22
  gene_term:
    preferred_term: PTPN22
    term:
      id: hgnc:9652
      label: PTPN22
  association: GWAS
  notes: Protein tyrosine phosphatase modulating T cell receptor signaling threshold
environmental:
- name: Vitamin D Deficiency
  influences_mechanisms:
  - target: Th1/Th17-Mediated Neuroinflammation
    environmental_effect: PREDISPOSES
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Graded below the Epstein-Barr link into this same node. The second item
      is the more interesting of the two and the reason this link is drawn at
      all: a low-frequency coding variant that raises the risk of vitamin D
      insufficiency also raises the odds of this disease, which is a
      genetic-instrument argument rather than another observational
      association. Both items stop at disease risk.
    evidence:
    - reference: PMID:28757204
      reference_title: "Low-Frequency Synonymous Coding Variation in CYP2R1 Has Large Effects on Vitamin D Levels and Risk of Multiple Sclerosis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "By analyzing 8,711 individuals, we showed that heterozygote carriers of this low-frequency variant have an increased risk of vitamin D insufficiency... Individuals carrying one copy of this variant also had increased odds of multiple sclerosis..."
      explanation: >-
        Carriers of a variant that increases the risk of vitamin D
        insufficiency also have increased odds of this disease. A genetic
        instrument, which is harder to confound than an observational
        association, but still measured against disease risk.
    - reference: PMID:20494325
      reference_title: "Vitamin D and multiple sclerosis."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Overall, the results of these studies support a protective effect of vitamin D, but there are uncertainties and many unanswered questions, including how vitamin D exerts a protective effect, how genetic variations modify the effect, and whether vitamin D can influence the course of MS progression."
      explanation: >-
        Review supporting a protective effect of vitamin D while listing the
        open questions, including how the effect is exerted. Its own
        uncertainty is why this link's intermediates are unknown.
  effect: Increased risk
  evidence:
  - reference: PMID:20494325
    reference_title: "Vitamin D and multiple sclerosis."
    supports: SUPPORT
    snippet: Overall, the results of these studies support a protective effect of vitamin D, but there are uncertainties and many unanswered questions, including how vitamin D exerts a protective effect, how genetic variations modify the effect, and whether vitamin D can influence the course of MS progression.
    explanation: The abstract suggests that adequate vitamin D nutrition can contribute to the prevention of multiple sclerosis, implying that vitamin D deficiency increases the risk.
  - reference: PMID:22906614
    reference_title: "Risk factors for multiple sclerosis: decreased vitamin D level and remote Epstein-Barr virus infection in the pre-clinical phase of multiple sclerosis."
    supports: SUPPORT
    snippet: 'Risk factors for multiple sclerosis: decreased vitamin D level and remote Epstein-Barr virus infection in the pre-clinical phase of multiple sclerosis.'
    explanation: The title directly states that decreased vitamin D levels are a risk factor for multiple sclerosis.
  - reference: PMID:28757204
    reference_title: "Low-Frequency Synonymous Coding Variation in CYP2R1 Has Large Effects on Vitamin D Levels and Risk of Multiple Sclerosis."
    supports: SUPPORT
    snippet: By analyzing 8,711 individuals, we showed that heterozygote carriers of this low-frequency variant have an increased risk of vitamin D insufficiency... Individuals carrying one copy of this variant also had increased odds of multiple sclerosis...
    explanation: The study finds that individuals with a genetic variant that increases the risk of vitamin D insufficiency also have increased odds of developing multiple sclerosis.
  exposure_term:
    preferred_term: Vitamin D exposure (deficiency)
    term:
      id: ECTO:9000133
      label: exposure to vitamin D
- name: Epstein-Barr Virus Infection
  influences_mechanisms:
  - target: Th1/Th17-Mediated Neuroinflammation
    environmental_effect: PREDISPOSES
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Graded above the vitamin D link into this same node, on evidence rather
      than on preference: this exposure has a quantified hazard, is described
      by its source as the strongest known risk factor for the disease, and is
      argued elsewhere to be necessary though not sufficient. The
      intermediates are nonetheless unknown, because no cited sentence follows
      the virus to myelin-reactive T cells; the route from infection to this
      node is exactly what the field is still arguing about.
    evidence:
    - reference: PMID:24289836
      reference_title: "Environmental factors in multiple sclerosis."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "The strongest known risk factor for MS is infection with Epstein-Barr virus (EBV). Compared with uninfected individuals, the hazard of developing MS is approximately 15-fold higher among individuals infected with EBV in childhood and about 30-fold higher among those infected with EBV in adolescence or later in life."
      explanation: >-
        Calls this the strongest known risk factor and quantifies it, with
        roughly fifteen-fold higher hazard after childhood infection and
        thirty-fold after adolescent or later infection.
    - reference: DOI:10.14288/1.0444003
      reference_title: "Vaccination against gammaherpesvirus attenuates viral enhanced disease in a murine model of multiple sclerosis"
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "MS does not develop in the absence of EBV exposure, and EBV is necessary, but insufficient on its own, to cause disease."
      explanation: >-
        States that the disease does not develop in the absence of this
        exposure and that the virus is necessary but insufficient alone. A
        necessity claim, from a model-organism thesis, so it is carried at
        partial and not alone.
  effect: Increased risk
  evidence:
  - reference: PMID:35145009
    reference_title: "New Evidence for Epstein-Barr Virus Infection as a Cause of Multiple Sclerosis."
    supports: SUPPORT
    snippet: New Evidence for Epstein-Barr Virus Infection as a Cause of Multiple Sclerosis.
    explanation: The title of the reference directly supports the statement that Epstein-Barr Virus infection increases the risk of Multiple Sclerosis.
  - reference: PMID:24289836
    reference_title: "Environmental factors in multiple sclerosis."
    supports: SUPPORT
    snippet: The strongest known risk factor for MS is infection with Epstein-Barr virus (EBV). Compared with uninfected individuals, the hazard of developing MS is approximately 15-fold higher among individuals infected with EBV in childhood and about 30-fold higher among those infected with EBV in adolescence or later in life.
    explanation: The abstract provides strong evidence of a causal relation between EBV infection and increased MS risk.
  - reference: PMID:36669485
    reference_title: "Virus exposure and neurodegenerative disease risk across national biobanks."
    supports: SUPPORT
    snippet: With recent findings connecting the Epstein-Barr virus to an increased risk of multiple sclerosis... We also replicated the Epstein-Barr/multiple sclerosis association.
    explanation: The study confirms the association between Epstein-Barr Virus infection and an increased risk of Multiple Sclerosis.
  - reference: PMID:37804765
    reference_title: "Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy."
    supports: SUPPORT
    snippet: Epstein-Barr virus (EBV) is a known risk factor for MS and seems to be a prerequisite for disease development.
    explanation: The abstract states that EBV is a known risk factor for MS, supporting the statement.
  - reference: PMID:21836034
    reference_title: "Epstein-Barr virus and multiple sclerosis."
    supports: SUPPORT
    snippet: There is strong evidence however that people with MS are more likely to report a past history of infectious mononucleosis (thought to represent initial EBV infection at an older age), and higher titres of EBV specific antibodies are associated with an increased risk of developing MS.
    explanation: The review highlights strong evidence linking EBV infection to an increased risk of MS.
  - reference: DOI:10.14288/1.0444003
    reference_title: Vaccination against gammaherpesvirus attenuates viral enhanced disease in a murine model of multiple sclerosis
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >
      MS does not develop in the absence of EBV exposure, and EBV is necessary,
      but insufficient on its own, to cause disease.
    explanation: >
      The deep-research artifact surfaced this model-organism thesis as an EBV
      prevention/mechanism result; the snippet supports EBV exposure as a
      necessary but not sufficient cofactor rather than a sole cause.
  - reference: PMID:35025605
    reference_title: "Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Risk of MS increased 32-fold after infection with EBV but was not increased after infection with other viruses, including the similarly transmitted cytomegalovirus."
    explanation: >-
      The primary longitudinal cohort behind the risk estimate the reviews above
      report second-hand: more than 10 million US military personnel, 955 of
      whom developed MS while serving. The comparison with cytomegalovirus,
      transmitted the same way, is what makes the association specific to EBV
      rather than to being infection-prone.
  exposure_term:
    preferred_term: Epstein-Barr virus exposure
    term:
      id: ECTO:3000001
      label: exposure to virus
computational_models:
- name: UISS-MS Agent-Based Treatment Simulator
  description: >-
    Multiscale, multi-compartment agent-based model of relapsing-remitting
    multiple sclerosis. Its physiology layer represents innate and adaptive
    immune agents; its MS disease layer represents antigen presentation,
    Th1/Th17 and B-cell responses, blood-brain-barrier migration, CNS
    inflammation, and oligodendrocyte loss; and its treatment layers simulate
    cladribine and ocrelizumab. Retrospective virtual cohorts were selected to
    match aggregate CLARITY and OPERA trial characteristics and outcomes.
  model_type: AGENT_BASED
  model_software: Universal Immune System Simulator (UISS)
  publication: PMID:37266405
  modeled_mechanisms:
  - target: Th1/Th17-Mediated Neuroinflammation
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    description: >-
      The disease layer explicitly represents cytokine-dependent Th1 and Th17
      differentiation, migration across the blood-brain barrier, reactivation
      in the CNS, and inflammatory interactions with microglia and other immune
      agents.
    limitations: >-
      The immune rules are a mechanistic abstraction assembled from a conceptual
      ontology rather than fitted to longitudinal cellular or cytokine data from
      individual patients. Validation is against aggregate relapse and safety
      outcomes in selected RRMS-like virtual populations, not direct
      measurements of Th1/Th17 states. Progressive MS and compartmentalized
      chronic CNS inflammation are outside the demonstrated validation scope.
    evidence:
    - reference: PMID:37266405
      reference_title: "Moving forward through the in silico modeling of multiple sclerosis: Treatment layer implementation and validation."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: >-
        Th17 cells secrete various cytokines, including IL-17, IL-6, IL-21,
        IL-22, IL-23, and TNF-α. Subsequently, these cells migrate across the
        blood-brain barrier (BBB) to the central nervous system (CNS) under the
        influence of specific cytokines, namely IL-17, IL-6, and IL-22, as well
        as IL-23, provided that the inhibitory effects of IL-10 are absent.
      explanation: >-
        Describes the Th17 cytokine and CNS-migration processes represented in
        the model's MS conceptual layer.
  - target: Demyelination
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    description: >-
      Immune-agent interactions drive loss of modeled oligodendrocytes, which is
      used as the simulation's cellular proxy for myelin injury and relapse.
    limitations: >-
      Demyelination is reduced to oligodendrocyte loss in a simulated 3-mm3
      white-matter volume. The model does not resolve myelin ultrastructure,
      tract-specific conduction, remyelination, or axonal injury, and the
      oligodendrocyte-loss threshold is not an individualized imaging model.
    readouts:
    - name: Oligodendrocyte loss during simulated relapse
      target: Demyelination
      direction: INCREASED
      interpretation: >-
        Rapid loss of modeled oligodendrocytes is the disease-layer readout for
        a demyelinating event; treatment benefit appears as fewer such losses.
      evidence:
      - reference: PMID:37266405
        reference_title: "Moving forward through the in silico modeling of multiple sclerosis: Treatment layer implementation and validation."
        supports: SUPPORT
        evidence_source: COMPUTATIONAL
        snippet: >-
          The plots represent the number of oligodendrocytes cells during time
          expressed in days, and relapse is shown as a rapid reduction in cell
          number.
        explanation: >-
          Defines the simulated oligodendrocyte-count change used to represent a
          relapse-associated demyelinating event.
    evidence:
    - reference: PMID:37266405
      reference_title: "Moving forward through the in silico modeling of multiple sclerosis: Treatment layer implementation and validation."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: >-
        In the CNS, activated helper T cells engage with resident microglia.
        Upon recognition of myelin antigens, the microglia are reactivated and
        produce specific cytokines (such as IL-1, IL-6, IL-12, TNF-α, IFN-γ,
        and IL-2) and chemokines that activate Th1 and Th17 cells, leading to an
        inflammatory cascade and subsequent destruction of oligodendrocytes.
      explanation: >-
        Connects the model's immune cascade to its explicit oligodendrocyte-loss
        representation.
  - target: Inflammatory Lesions
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    description: >-
      UISS-MS converts sufficiently large simulated oligodendrocyte-loss events
      into MRI-detectable relapses, providing a coarse lesion-level output for
      comparison with clinical-trial relapse data.
    limitations: >-
      A fixed loss of 50,000 oligodendrocytes is used as the MRI-detection
      threshold. This is a derived event proxy, not a spatial lesion-growth or
      MRI-physics model, and it does not reproduce lesion topography, contrast
      enhancement, immune-cell composition, chronic-active rims, or lesion-wise
      uncertainty.
    readouts:
    - name: MRI-detectable relapse event
      target: Inflammatory Lesions
      interpretation: >-
        An oligodendrocyte-loss event at or above the fixed threshold is counted
        as one or more MRI-detectable lesions for trial-level relapse analysis.
      evidence:
      - reference: PMID:37266405
        reference_title: "Moving forward through the in silico modeling of multiple sclerosis: Treatment layer implementation and validation."
        supports: SUPPORT
        evidence_source: COMPUTATIONAL
        snippet: >-
          The minimum MRI detectable threshold is set as a lesion involving at
          least 50 × 103 ODC, which assumes a uniform distribution of ODCs in
          the white matter tissue.
        explanation: >-
          Gives the model's explicit threshold for translating oligodendrocyte
          loss into an MRI-detectable lesion event.
    evidence:
    - reference: PMID:37266405
      reference_title: "Moving forward through the in silico modeling of multiple sclerosis: Treatment layer implementation and validation."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: >-
        Other forms are related to a consistent oligodendrocytes loss that
        instead provokes an MRI-detectable lesion. Only relapses that are
        detectable by MRI were considered in our analysis.
      explanation: >-
        Establishes the lesion proxy and the MRI-detectable subset used in the
        reported trial comparisons.
  variables:
  - name: Activated Th1-cell population
    dataset_identifier: Th1
    description: Modeled Th1 immune-agent population and activation state.
    unit: simulated cells
  - name: Activated Th17-cell population
    dataset_identifier: Th17
    description: Modeled Th17 immune-agent population and activation state.
    unit: simulated cells
  - name: Oligodendrocyte count
    dataset_identifier: ODC
    description: >-
      Cellular state whose rapid loss represents demyelinating relapse in the
      simulated white-matter compartment.
    unit: cells
  - name: MRI-detectable lesion event
    description: >-
      Event declared when oligodendrocyte loss reaches the fixed detection
      threshold.
    unit: event count
  - name: Annualized relapse rate
    dataset_identifier: ARR
    description: Trial-level relapse-rate output used for OPERA comparison.
    unit: relapses per patient-year
  - name: Absolute lymphocyte count
    dataset_identifier: ALC
    description: Treatment-safety output used to grade cladribine-associated lymphocytopenia.
    unit: cells/uL
  findings:
  - statement: >-
      In the OPERA simulations, predicted annualized relapse rates were 0.193
      for ocrelizumab versus 0.16 observed and 0.349 for interferon beta-1a
      versus 0.29 observed; the predicted relative reduction was 45.7% versus
      50% in the clinical trial.
    evidence:
    - reference: PMID:37266405
      reference_title: "Moving forward through the in silico modeling of multiple sclerosis: Treatment layer implementation and validation."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: >-
        As one can envisage from the analysis of Table 1, the ARR among patients
        receiving ocrelizumab at 96 weeks is predicted to be 0.193 against real
        Opera RCT of 0.16. ARR IFNβ− 1a is predicted to be 0.349, compared
        with real Opera RCT 0.29. The in silico trial of the Opera study
        predicted a relative reduction of 45.7 % on ocrelizumab compared to
        IFNβ− 1a. This is in excellent agreement with the 50 % relative
        reduction predicted in the real RCT, given that the digital patients can
        own more variability than those enrolled in the Opera RCT.
      explanation: >-
        Supplies the exact simulated and observed OPERA relapse-rate comparisons.
  - statement: >-
      Retrospective virtual cohorts reproduced the reported directions of
      cladribine and ocrelizumab treatment outcomes.
    evidence:
    - reference: PMID:37266405
      reference_title: "Moving forward through the in silico modeling of multiple sclerosis: Treatment layer implementation and validation."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: >-
        The obtained results mirror those of the clinical trials, demonstrating
        that UISS-MS can correctly simulate the mechanisms of action and
        outcomes of the treatments.
      explanation: >-
        States the publication's retrospective treatment-validation conclusion.
  evidence:
  - reference: PMID:37266405
    reference_title: "Moving forward through the in silico modeling of multiple sclerosis: Treatment layer implementation and validation."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      Universal Immune System Simulator is an agent-based model that simulates
      the human immune system dynamics under physiological conditions and during
      several diseases, including multiple sclerosis.
    explanation: >-
      Establishes UISS-MS as a disease-relevant agent-based immune-system model.
  notes: >-
    A curator search on 2026-08-20 identified no public UISS-MS source
    repository, executable archive, or software license. The article is open
    access, but that does not license the simulator. Although the authors
    describe a digital-twin use case, this study had only population-level
    demographic inputs: thousands of immune repertoires were generated and
    subsets were selected to match aggregate trial behavior. It therefore does
    not validate one-to-one patient twins or prospective individual
    counterfactuals. The CLARITY cohort was used in selection/calibration before
    the extension analysis, and formal VVUQ and regulatory credibility
    assessment remained future work.
- name: Virtual Multiple Sclerosis Patient Whole-Brain Model
  description: >-
    Subject-specific delayed whole-brain model that couples 84 noisy
    Stuart-Landau oscillators according to each participant's DTI-derived
    connectome. Simulation-based Bayesian inference uses source-reconstructed
    MEG alpha-spectrum features to estimate a global coupling parameter and one
    average whole-brain conduction velocity for each participant.
  model_type: DIGITAL_TWIN
  repository_url: https://github.com/ins-amu/virtual_ms/tree/67cb165d2631f73cfae79643accf7bae3e7b4ef1
  base_model: Delayed Stuart-Landau subject-specific whole-brain network
  model_software: Python, C++/SWIG, Jupyter, PyTorch sbi
  model_format: Python/C++ source and Jupyter notebooks
  publication: PMID:38974971
  modeled_mechanisms:
  - target: Demyelination
    relationship: MEASURES
    fidelity: MODERATE
    description: >-
      The inverse model treats slower large-scale signal propagation as a
      functional consequence of myelin damage and infers an individual average
      conduction velocity from the participant's connectome and MEG spectrum.
    limitations: >-
      The model does not simulate immune attack, myelin loss, lesion formation,
      remyelination, or axonal injury. It collapses spatially heterogeneous
      conduction into one homogeneous whole-brain velocity, and alpha-spectrum
      changes can also arise from excitation/inhibition balance, 1/f structure,
      or thalamic-loop changes. The evidence comes from 18 patients and 20
      controls at one site; EDSS was available for 17 patients, and no external
      or longitudinal validation cohort was used.
    readouts:
    - name: Inferred average whole-brain conduction velocity
      target: Demyelination
      direction: DECREASED
      interpretation: >-
        A lower inferred velocity is interpreted as the aggregate functional
        effect of myelin damage, not a direct measurement of lesion-wise
        demyelination.
      evidence:
      - reference: PMID:38974971
        reference_title: "The virtual multiple sclerosis patient."
        supports: SUPPORT
        evidence_source: COMPUTATIONAL
        snippet: >-
          The posterior distribution of the parameter G, which scales the
          structural connectivity of subjects, demonstrated non-significant
          changes (p = 0.87), whereas the posterior distribution of averaged
          velocities V significantly decreased (p < 0.01) in MS patients as
          compared to the control group.
        explanation: >-
          Reports the disease-direction result for the inferred conduction
          velocity readout.
    evidence:
    - reference: PMID:38974971
      reference_title: "The virtual multiple sclerosis patient."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: >-
        In conclusion, we propose a principled way to link the most relevant
        physiopathological feature in MS, namely the slower conduction
        velocities across the brain network induced by myelin damage, to a
        large-scale observable quantity, that is the modification of the
        frequency spectrum.
      explanation: >-
        Directly connects myelin damage, slower conduction, and the spectral
        observable used for model inversion.
  variables:
  - name: Global coupling strength
    dataset_identifier: G
    description: Scalar multiplying each subject's structural-connectivity matrix.
    unit: model coupling parameter
  - name: Average whole-brain conduction velocity
    dataset_identifier: V
    description: >-
      Subject-level homogeneous conduction-speed parameter inferred by
      simulation-based Bayesian inversion.
    unit: m/s
  - name: Alpha peak frequency
    dataset_identifier: peak_frequency
    description: Frequency of the median source-reconstructed MEG alpha-spectrum peak.
    unit: Hz
  - name: Alpha peak amplitude
    dataset_identifier: peak_amplitude
    description: Peak amplitude of the median 8-13-Hz power spectral density.
    unit: power spectral density
  - name: Total alpha power
    dataset_identifier: total_alpha_power
    description: Area under the median power spectral density from 8 to 13 Hz.
    unit: integrated power spectral density
  findings:
  - statement: >-
      Inferred average conduction velocity was lower in the 18-person MS group
      than in 20 controls, while global coupling did not differ.
    evidence:
    - reference: PMID:38974971
      reference_title: "The virtual multiple sclerosis patient."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: >-
        The posterior distribution of the parameter G, which scales the
        structural connectivity of subjects, demonstrated non-significant
        changes (p = 0.87), whereas the posterior distribution of averaged
        velocities V significantly decreased (p < 0.01) in MS patients as
        compared to the control group.
      explanation: >-
        Gives the group comparisons for both inferred model parameters.
    - reference: PMID:38974971
      reference_title: "The virtual multiple sclerosis patient."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: >-
        To test our hypotheses, we used source-reconstructed MEG data and
        tractographies from 18 MS patients and 20 healthy controls.
      explanation: >-
        Supplies the sample sizes stated in the finding.
  - statement: >-
      Inferred conduction velocities were stronger predictors of clinical
      disability than structural damage in this cohort.
    evidence:
    - reference: PMID:38974971
      reference_title: "The virtual multiple sclerosis patient."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: >-
        Remarkably, these velocities proved superior predictors of clinical
        disability compared to structural damage.
      explanation: >-
        States the reported clinical-prediction comparison for inferred velocity.
  evidence:
  - reference: PMID:38974971
    reference_title: "The virtual multiple sclerosis patient."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      In this study, we integrate diffusion tensor immaging (DTI) and
      magnetoencephalography (MEG) data into individualized virtual brain models
      to estimate conduction velocities for MS patients and controls.
    explanation: >-
      Establishes the individualized multimodal model and its inferred quantity.
  notes: >-
    Curator inspection on 2026-08-20 used repository commit
    67cb165d2631f73cfae79643accf7bae3e7b4ef1 (also tagged v1.0). No LICENSE file
    or license grant was present; an MIT classifier in setup.py is not sufficient
    to license the code. The repository contains the delayed Stuart-Landau
    forward solver and an SBI demonstration, but not the clinical connectomes,
    MEG inputs, trained posterior, or complete 38-subject analysis. In the
    curator's smoke test, the default install failed to build the SWIG extension;
    after a manual build and dependency repairs, a synthetic three-node forward
    simulation produced finite time series and an alpha-band PSD. Curator
    comparison also found material paper/code differences in simulation
    duration, noise scale, priors, alpha band, and feature count. Reproducing the
    clinical findings therefore requires restricted data and missing workflow
    components. The paper reports a patent application and calls for larger
    multicenter replication.
- name: Lesion-Aware Personalized Whole-Brain Conduction-Delay Model
  description: >-
    Direct successor to the Virtual Multiple Sclerosis Patient model. It retains
    each participant's 84-region DTI connectome and noisy Stuart-Landau dynamics
    but augments distance-derived edge delays based on a shared whole-brain
    velocity with an additive tract-specific term derived from the fraction of
    each tract intersecting the participant's FLAIR lesion mask. Simulation-based
    inference estimates the patient-specific strength of the lesion-to-delay
    relationship.
  model_type: DIGITAL_TWIN
  base_model: Virtual Multiple Sclerosis Patient whole-brain model (PMID:38974971)
  model_software: Custom Stuart-Landau simulator with the SBI toolbox
  publication: PMID:40317832
  modeled_mechanisms:
  - target: Demyelination
    relationship: MEASURES
    fidelity: MODERATE
    description: >-
      The model maps the fraction of each white-matter tract occupied by a
      patient-specific lesion to an additional edge-specific conduction delay,
      then infers a subject-level lesion-effect parameter from MEG spectra.
    limitations: >-
      FLAIR lesion fraction is an imaging proxy, not a direct measure of myelin
      thickness, axon diameter, or active inflammation. The model does not
      generate lesions or simulate immune attack, remyelination, axonal damage,
      or progression. One scalar gamma applies the same lesion-to-delay rule to
      all affected tracts, source reconstruction is vulnerable to volume
      conduction, and alternative mechanisms can alter alpha spectra. The same
      18-patient/20-control source cohort as the 2024 study was used, without
      longitudinal or external validation.
    readouts:
    - name: Lesion-weighted tract conduction delay
      target: Demyelination
      direction: INCREASED
      interpretation: >-
        More lesion involvement adds a larger modeled delay on the affected
        tract; this is a personalized functional proxy rather than direct
        lesion-wise electrophysiology.
      evidence:
      - reference: PMID:40317832
        reference_title: "Mapping Brain Lesions to Conduction Delays: The Next Step for Personalized Brain Models in Multiple Sclerosis."
        supports: SUPPORT
        evidence_source: COMPUTATIONAL
        snippet: >-
          In this work, we use large-scale brain models and Bayesian model
          inversion to estimate how myelin lesions translate to longer
          conduction delays across the damaged tracts.
        explanation: >-
          Directly supports the increased-delay direction of the lesion-weighted
          tract readout.
    - name: Alpha-spectrum peak amplitude as lesion-effect weight increases
      target: Demyelination
      direction: DECREASED
      interpretation: >-
        Lower simulated alpha peak amplitude with larger lesion-effect weight is
        the spectral feature used to invert the patient-specific parameter.
      evidence:
      - reference: PMID:40317832
        reference_title: "Mapping Brain Lesions to Conduction Delays: The Next Step for Personalized Brain Models in Multiple Sclerosis."
        supports: SUPPORT
        evidence_source: COMPUTATIONAL
        snippet: >-
          In Figure 2c, one can observe the changes in the amplitude and
          frequency of the peak, as well as the variations in the area under the
          PSD, calculated from the alpha spectrum as a function of γ. All these
          spectral features decrease as γ increases.
        explanation: >-
          Gives the simulated direction of alpha peak frequency, amplitude, and
          area as the lesion-effect parameter increases.
    evidence:
    - reference: PMID:40317832
      reference_title: "Mapping Brain Lesions to Conduction Delays: The Next Step for Personalized Brain Models in Multiple Sclerosis."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: >-
        In this work, we use large-scale brain models and Bayesian model
        inversion to estimate how myelin lesions translate to longer conduction
        delays across the damaged tracts.
      explanation: >-
        Establishes the model's lesion-informed, patient-specific conduction
        delay objective.
  variables:
  - name: Tract lesion fraction
    dataset_identifier: l_jk
    description: >-
      Fraction of voxels in the tract between regions j and k that intersect the
      participant's FLAIR lesion mask.
    unit: proportion
  - name: Lesion-to-delay weight
    dataset_identifier: gamma
    description: >-
      Subject-level parameter controlling how strongly tract lesion fraction
      increases propagation delay.
    unit: model delay parameter
  - name: Edge-specific conduction delay
    dataset_identifier: tau_jk
    description: >-
      Baseline distance-over-velocity delay plus the lesion-weighted delay term
      for a structural connection.
    unit: s
  - name: Global coupling strength
    dataset_identifier: G
    description: Scalar multiplying the participant's structural-connectivity matrix.
    unit: model coupling parameter
  - name: Alpha peak amplitude
    dataset_identifier: peak_amplitude
    description: Empirical or simulated alpha-spectrum peak used in model inversion.
    unit: power spectral density
  findings:
  - statement: >-
      The inferred lesion-to-delay weight correlated inversely with alpha peak
      power (r=-0.83), whereas total lesion load did not correlate with alpha
      peak power or the inferred weight.
    evidence:
    - reference: PMID:40317832
      reference_title: "Mapping Brain Lesions to Conduction Delays: The Next Step for Personalized Brain Models in Multiple Sclerosis."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: >-
        We show that the most plausible γ values for the subjects relate, as
        expected, to the power in the alpha band (Figure 4a) (r = −0.83,
        p = 0.00). However, the lesion load itself does not relate to the
        amplitude of the alpha-peak nor to the γ parameter (r = 0.00, p = 0.9,
        r = −0.38, p = 0.12, respectively), showing that the weighting of the
        lesions, that is, the effect that they exert on the slowing of conduction
        velocities, is likely topography-dependent and, as such, patient
        specific.
      explanation: >-
        Supplies the spectral correlation and the negative total-lesion-load
        comparisons that motivate tract-specific personalization.
  - statement: >-
      Adding the inferred lesion-effect parameter to the cross-sectional EDSS
      model yielded leave-one-out R2=0.29882 and adjusted R2=0.018348, but its
      coefficient was not statistically significant (p=0.1784).
    evidence:
    - reference: PMID:40317832
      reference_title: "Mapping Brain Lesions to Conduction Delays: The Next Step for Personalized Brain Models in Multiple Sclerosis."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: >-
        The parameter γ enhances prediction accuracy in both classical
        multilinear (R2 = 0.2793; AdjR2 = 0.017226) (age β = 0.0227
        ρ = 0.7328; duration β = 0.0015 ρ = 0.7547; lesion load β = −0.0000
        ρ = 0.5921; γ β = −3.3099 ρ = 0.1366) and cross-validated models
        (R2 = 0.29882; AdjR2 = 0.018348) (age β = 0.0327 ρ = 0.7229;
        duration β = 0.0011 ρ = 0.7421; lesion load β = 0.0000 ρ = 0.5968;
        γ β = −3.3972 ρ = 0.1784).
      explanation: >-
        Preserves the weak adjusted fit and nonsignificant gamma coefficient
        that qualify the abstract's cross-sectional prediction claim.
    - reference: PMID:40317832
      reference_title: "Mapping Brain Lesions to Conduction Delays: The Next Step for Personalized Brain Models in Multiple Sclerosis."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: >-
        The model has been validated using a leave-one-out cross-validation
        scheme.
      explanation: >-
        Identifies the cross-validation scheme used for the reported fit.
    - reference: PMID:40317832
      reference_title: "Mapping Brain Lesions to Conduction Delays: The Next Step for Personalized Brain Models in Multiple Sclerosis."
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: >-
        Adding γ to the predictive model enhances the predictive power on
        clinical disability, although without reaching statistical significance,
        as shown in Supporting Information Figure S2.
      explanation: >-
        Grounds the nonsignificant result in the authors' prose rather than only
        interpreting the reported coefficient statistic.
  evidence:
  - reference: PMID:40317832
    reference_title: "Mapping Brain Lesions to Conduction Delays: The Next Step for Personalized Brain Models in Multiple Sclerosis."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      This study represents the initial exploration showcasing the
      location-specific impact of myelin lesions on conduction delays, thereby
      enhancing the customization of models for individuals with multiple sclerosis.
    explanation: >-
      States the patient-specific purpose and exploratory scope of the model.
  notes: >-
    A curator search on 2026-08-20 identified no paper-specific code repository
    or executable model archive, and the clinical inputs are available only on
    request. Curator inspection found that the open VBI package contains generic
    Stuart-Landau and SBI components but not this paper's lesion-specific
    gamma-by-tract formulation, so it is not cited as the model artifact. The
    article is CC BY 4.0, which licenses the paper rather than an unreleased
    implementation. Synthetic parameter recovery had slope 0.8 and showed
    boundary bias. The clinical analysis reuses the small cross-sectional source
    cohort from the 2024 model; the gamma term was not a statistically
    significant EDSS predictor, and longitudinal validation is still needed.
treatments:
- name: Disease-Modifying Therapies (DMTs)
  description: Medications that can slow the progression of the disease and reduce the frequency and severity of relapses.
  examples:
  - Interferon-beta
  - Glatiramer Acetate
  - Natalizumab
  - Fingolimod
  evidence:
  - reference: PMID:12894379
    reference_title: "Current disease-modifying therapies in multiple sclerosis."
    supports: SUPPORT
    snippet: In recent years, the usefulness of interferon beta and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis (RRMS) has been established.
    explanation: The reference confirms the efficacy of interferon beta and glatiramer acetate in treating RRMS, which aligns with the statement about DMTs reducing the frequency and severity of relapses.
  - reference: PMID:24494618
    reference_title: "Multiple sclerosis update."
    supports: SUPPORT
    snippet: Diseasemodifying drugs (DMDs) that reduce the frequency of relapses, development of brain lesions, and progression of disability are the standard of care for relapsing forms of MS, and the use of DMDs should be initiated as early as possible
    explanation: The reference supports the statement by indicating that DMDs reduce the frequency of relapses and progression of disability in MS.
  - reference: PMID:29921609
    reference_title: "Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data."
    supports: SUPPORT
    snippet: Those using the higher efficacy (category 3) DMTs, particularly fingolimod and natalizumab, reported significant increases in amount of work, work attendance and work productivity, suggesting they have important beneficial effects on work life in people with MS.
    explanation: The reference supports the statement by highlighting the beneficial effects of fingolimod and natalizumab on patients' work life, indirectly supporting their role in reducing the severity of relapses.
  - reference: PMID:27549763
    reference_title: "Disease modifying therapies for relapsing multiple sclerosis."
    supports: SUPPORT
    snippet: Disease modifying therapies (DMTs) approved for relapsing multiple sclerosis interfere with a variety of immunological mechanisms to reduce rates of relapse, accumulation of disease burden measured by magnetic resonance imaging (MRI), and decline in neurological function over the two to three year duration of typical randomized controlled trials.
    explanation: The reference supports the statement regarding the reduction of relapse rates and disease burden but notes that the benefits on long-term disability reduction are less clear.
  - reference: PMID:32560364
    reference_title: "Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis."
    supports: SUPPORT
    snippet: Several FDA-approved medications seek to alleviate disease progression by reducing the impact of such factors as demyelination and neurodegeneration
    explanation: The reference supports the statement by indicating that FDA-approved medications aim to alleviate disease progression and reduce neurodegeneration, which aligns with the description of DMTs.
  - reference: PMID:39737584
    reference_title: "Disease-modifying therapy in multiple sclerosis: recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The initiation of DMT with interferon beta or glatiramer acetate may be considered in appropriate cases in patients with CIS who do not meet the criteria for the diagnosis of MS."
    explanation: The Polish Neurological Society MS recommendations advise initiating disease-modifying therapy (e.g., interferon beta or glatiramer acetate) in appropriate CIS patients.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Th1/Th17-Mediated Neuroinflammation
    treatment_effect: INHIBITS
    description: >-
      Disease-modifying therapies (interferons, natalizumab, fingolimod, and
      others) suppress autoreactive Th1 and Th17 lymphocyte trafficking into
      the CNS and reduce pro-inflammatory cytokine production that drives
      demyelinating lesion formation.
  - target: Inflammatory Lesions
    treatment_effect: INHIBITS
    description: >-
      DMTs reduce the frequency of new gadolinium-enhancing lesions by limiting
      CNS immune cell infiltration and the inflammatory cascade that underlies
      acute demyelinating plaque formation.
- name: Anti-CD20 B-cell Depletion Therapy
  description: >-
    Anti-CD20 monoclonal antibodies (ocrelizumab, ofatumumab) selectively
    deplete CD20+ B lymphocytes, providing direct interventional validation of
    the B-cell arm of MS pathogenesis. They markedly reduce relapse rate and MRI
    activity in relapsing MS, and ocrelizumab is the first therapy shown to
    modestly slow confirmed disability progression in primary progressive MS.
  examples:
  - Ocrelizumab
  - Ofatumumab
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ocrelizumab
      term:
        id: NCIT:C66250
        label: Ocrelizumab
    - preferred_term: ofatumumab
      term:
        id: NCIT:C66952
        label: Ofatumumab
  target_mechanisms:
  - target: Inflammatory Lesions
    treatment_effect: INHIBITS
    description: >-
      Depletion of CD20+ B cells reduces the formation of new
      gadolinium-enhancing inflammatory lesions and lowers the annualized
      relapse rate in relapsing MS.
  evidence:
  - reference: PMID:28002679
    reference_title: "Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells."
    explanation: The OPERA phase 3 trials establish ocrelizumab as a selective CD20+ B-cell-depleting antibody targeting the B-cell arm of MS.
  - reference: PMID:28002679
    reference_title: "Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The annualized relapse rate was lower with ocrelizumab than with interferon beta-1a in trial 1 (0.16 vs. 0.29; 46% lower rate with ocrelizumab"
    explanation: In OPERA I, ocrelizumab reduced the annualized relapse rate by 46% versus interferon beta-1a, demonstrating efficacy of B-cell depletion in relapsing MS.
  - reference: PMID:28002688
    reference_title: "Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We studied ocrelizumab, a humanized monoclonal antibody that selectively depletes CD20-expressing B cells, in the primary progressive form of the disease."
    explanation: The ORATORIO trial tested selective CD20+ B-cell depletion in primary progressive MS.
  - reference: PMID:28002688
    reference_title: "Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The percentage of patients with 12-week confirmed disability progression was 32.9% with ocrelizumab versus 39.3% with placebo"
    explanation: In ORATORIO, ocrelizumab modestly reduced 12-week confirmed disability progression in primary progressive MS (32.9% vs 39.3%, hazard ratio 0.76), the first DMT with a positive PPMS trial.
  - reference: PMID:32757523
    reference_title: "Ofatumumab versus Teriflunomide in Multiple Sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells."
    explanation: ASCLEPIOS establishes ofatumumab as a subcutaneous anti-CD20 B-cell-depleting antibody for relapsing MS.
  - reference: PMID:32757523
    reference_title: "Ofatumumab versus Teriflunomide in Multiple Sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "relapse rates in the ofatumumab and teriflunomide groups were 0.11 and 0.22"
    explanation: In ASCLEPIOS, ofatumumab roughly halved the annualized relapse rate versus teriflunomide (0.11 vs 0.22), confirming the class efficacy of anti-CD20 B-cell depletion.
  - reference: PMID:21555250
    reference_title: "Treatment of multiple sclerosis with anti-CD20 antibodies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "insights from these studies have underscored the importance of non-antibody mediated functions of B cells"
    explanation: >-
      Says which B-cell function the response implicates, which the efficacy
      trials above do not. Anti-CD20 depletes CD20+ B cells while sparing
      CD20-negative plasma cells, the main antibody producers, so the benefit
      points to antigen presentation and cytokine secretion rather than to
      autoantibody production.
- name: Symptomatic Treatments
  description: Range of therapies to manage symptoms like spasticity, pain, fatigue, and bladder issues.
  examples:
  - Muscle Relaxants
  - Physical Therapy
  - Pain Management
  evidence:
  - reference: PMID:9817541
    reference_title: "Multiple sclerosis: symptomatic therapies."
    supports: SUPPORT
    snippet: Management of symptoms, however, can help everyone with the disease. Several new therapies, including tizanidine, intrathecal baclofen, botulinum toxin injections, gabapentin, ondansitron, thalamic stimulation, and lamotrigine, increase our treatment options.
    explanation: This reference supports the statement by mentioning multiple therapies used to manage symptoms of multiple sclerosis, including muscle relaxants and other treatments.
  - reference: PMID:36807901
    reference_title: "Spasticity evaluation and management tools."
    supports: SUPPORT
    snippet: Therapeutic options exist for the treatment of spasticity along a broad spectrum from nonpharmacologic to interventional procedures. Treatment strategies may include exercise, physical agent modalities, oral medications, injections, pumps, and surgery.
    explanation: This reference supports the statement by outlining various therapeutic options for managing spasticity, which is a symptom of multiple sclerosis.
  - reference: PMID:12926840
    reference_title: "Reflexology treatment relieves symptoms of multiple sclerosis: a randomized controlled study."
    supports: SUPPORT
    snippet: Specific reflexology treatment was of benefit in alleviating motor; sensory and urinary symptoms in MS patients.
    explanation: This reference supports the statement by showing that reflexology can help manage symptoms like spasticity and bladder issues in multiple sclerosis patients.
  - reference: PMID:26611270
    reference_title: "Country break-out session highlights."
    supports: SUPPORT
    snippet: Individuals with multiple sclerosis (MS) spasticity present a wide range of symptoms and disability levels that are frequently challenging to manage.
    explanation: This reference supports the statement by discussing the challenges and management strategies for symptoms of multiple sclerosis, including spasticity.
  - reference: PMID:35102733
    reference_title: "Management of bladder dysfunction in multiple sclerosis: a systematic review and meta-analysis of studies regarding bladder rehabilitation."
    supports: SUPPORT
    snippet: The present study suggests the need of a specific therapeutic protocol, based on the degree of disability and symptom complexity in patients with MS-related neurogenic lower urinary tract dysfunction (NLUTD).
    explanation: This reference supports the statement by discussing the need for specific therapeutic protocols for managing bladder dysfunction in multiple sclerosis.
  - reference: PMID:22721366
    reference_title: "[Non-medicinal treatments of spasticity in multiple sclerosis]."
    supports: SUPPORT
    snippet: Non-medicinal treatments of spasticity may be proposed in patients with multiple sclerosis as either an adjunct to pharmacological treatments or the first line of treatment.
    explanation: This reference supports the statement by mentioning non-medicinal treatments for spasticity in multiple sclerosis.
  - reference: PMID:11898533
    reference_title: "Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis."
    supports: SUPPORT
    snippet: Among the more common symptoms is spasticity. Despite a lack of full knowledge of the physiology causing this phenomenon, successful treatments have been developed.
    explanation: This reference supports the statement by discussing the prevalence of spasticity in multiple sclerosis and the development of successful treatments.
  - reference: PMID:16168933
    reference_title: "Symptomatic therapy and neurorehabilitation in multiple sclerosis."
    supports: SUPPORT
    snippet: 'First, we review treatment of the main symptoms of MS: fatigue, bladder and bowel disturbances, sexual dysfunction, cognitive and affective disorders, and spasticity.'
    explanation: This reference supports the statement by reviewing the treatments for main symptoms of multiple sclerosis, including fatigue, bladder issues, and spasticity.
  - reference: PMID:26166264
    reference_title: "Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis."
    supports: SUPPORT
    snippet: In this review, the effects of Sativex(®) oromucosal spray on symptoms and functional impairment associated with MS-related spasticity were examined
    explanation: This reference supports the statement by discussing the use of Sativex for managing symptoms associated with multiple sclerosis spasticity.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
- name: Physical Therapy and Rehabilitation
  description: Exercise programs and physical therapy to maintain mobility, strength, and function.
  examples:
  - Exercise therapy
  - Gait training
  - Balance exercises
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
- name: Corticosteroids
  description: Used to reduce inflammation and speed recovery during acute exacerbations.
  examples:
  - Prednisone
  - Methylprednisolone
  evidence:
  - reference: PMID:17920542
    reference_title: "Corticosteroids for multiple sclerosis: I. Application for treating exacerbations."
    supports: SUPPORT
    snippet: The treatment of MS exacerbations with anti-inflammatory agents such as corticosteroids and adrenocorticotropic hormone has represented an established practice throughout the neurology community.
    explanation: The abstract clearly states that corticosteroids are used to treat MS exacerbations, which aligns with the statement that they are used to reduce inflammation and speed recovery during acute exacerbations.
  treatment_term:
    preferred_term: systemic corticosteroid therapy
    term:
      id: NCIT:C122080
      label: Systemic Corticosteroid Therapy
  target_mechanisms:
  - target: Inflammatory Lesions
    treatment_effect: INHIBITS
    description: >-
      High-dose corticosteroids rapidly reduce CNS endothelial permeability and
      inflammatory cell infiltration, shrinking gadolinium-enhancing lesions and
      hastening recovery from acute MS relapses.
disease_term:
  preferred_term: multiple sclerosis
  term:
    id: MONDO:0005301
    label: multiple sclerosis
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
  - classification_value: IMMUNE_RHEUMATOLOGIC
discussions:
- discussion_id: gap_ms_c1q_eae_human_translation
  prompt: >-
    Does the causal C1q-to-MIMS mechanism demonstrated by microglia-specific C1q
    ablation and therapeutic blockade in mouse EAE operate at human chronic
    active lesion rims and contribute to PIRA?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Compartmentalized CNS Inflammation
  - pathophysiology#Axonal Damage
  rationale: >-
    Direct perturbation evidence exists in mouse EAE, so the gap is not absence
    of causal evidence. The unresolved issue is human translation and
    compartment specificity: the lesion-rim study implicates C1q in MIMS, while
    higher bulk CSF C1q predicted less progression in PPMS. Human lesion-edge
    perturbation or spatially resolved target-engagement data are needed to
    determine whether local microglial C1q has a different role from CSF C1q.
  evidence:
  - reference: PMID:34497421
    reference_title: "A lymphocyte-microglia-astrocyte axis in chronic active multiple sclerosis."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We identify complement component 1q (C1q) as a critical mediator of MIMS activation, validated immunohistochemically in MS tissue, genetically by microglia-specific C1q ablation in mice with experimental autoimmune encephalomyelitis, and therapeutically by treating chronic experimental autoimmune encephalomyelitis with C1q blockade."
    explanation: Establishes causal perturbation evidence in mouse EAE.
  - reference: PMID:38912898
    reference_title: "Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "increased CSF C1q levels predicted lower disability progression (adjusted OR 0.41; 95% CI 0.17-0.86; p = 0.025)"
    explanation: Shows that human CSF C1q has a protective prognostic association, motivating compartment-resolved testing.
- discussion_id: controversy_ms_pira_anatomical_substrate
  prompt: >-
    How much PIRA is attributable to chronic active white-matter lesion-rim
    inflammation versus spinal-cord and gray-matter degeneration?
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - pathophysiology#Compartmentalized CNS Inflammation
  - pathophysiology#Axonal Damage
  rationale: >-
    Paramagnetic rim lesions predict PIRA, but independent imaging cohorts find
    spinal-cord atrophy and cortical/deep-gray-matter degeneration to be the
    strongest predictors of severity and progression. These substrates may be
    complementary or competing, and their relative causal contribution remains
    unresolved.
  evidence:
  - reference: PMID:41527428
    reference_title: "Assessing the Relative Importance of Imaging and Serum Biomarkers in Capturing Disability, Cognitive Impairment, and Clinical Progression in Multiple Sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Spinal cord atrophy consistently emerged as the strongest predictor of disability severity and predicted PIRA, along with cortical thinning and subcortical atrophy - particularly in deep gray matter."
    explanation: Identifies cord and gray-matter degeneration as strong alternative or complementary PIRA substrates.
  - reference: PMID:41666922
    reference_title: "Choroid plexus enlargement associates with serum neurofilament and predicts relapse-free progression in multiple sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "High CP volume confers a 1.8-fold increased risk of disability worsening and a 2.7-fold increased risk of progression independent of relapse activity."
    explanation: >-
      Adds a third candidate substrate to the same open question: choroid plexus
      enlargement, measured in a prospective multicentre cohort of 434 people
      with MS, predicts relapse-independent progression roughly as strongly as
      the rim-lesion and cord-atrophy markers already listed here. The paper
      reports a prognostic association and a correlation with serum
      neurofilament light chain; it does not establish a CSF-inflammatory
      mechanism, so this is recorded as a competing predictor rather than as a
      causal step.
- discussion_id: controversy_ms_inside_out_versus_outside_in
  prompt: >-
    Does MS begin with a peripheral autoimmune attack on normal myelin
    (outside-in), or with a primary CNS cytodegenerative lesion whose released
    myelin antigen provokes secondary autoimmunity (inside-out)?
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - pathophysiology#Demyelination
  - pathophysiology#Th1/Th17-Mediated Neuroinflammation
  - pathophysiology#EBNA1-GlialCAM Molecular Mimicry
  rationale: >-
    The canonical hypothesis in this entry assumes the outside-in ordering. A
    competing inside-out account holds that a primary oligodendrocyte or myelin
    lesion comes first and that autoimmunity is a physiological response to
    excess antigen turnover in already-diseased tissue. The disagreement is not
    academic: it decides whether the therapeutic target is immunosuppression or
    myelin stabilization and neuroprotection, and it may explain why
    anti-inflammatory therapy does not arrest progressive disease. It is
    unresolved in humans, because both positions rest on model systems and on
    post-mortem tissue that cannot time the two events. Note that the leading
    inside-out review reports myelin blistering in normal-appearing white
    matter but does not show it precedes immune infiltration; treating that
    ordering as observed, as the 2026 OpenScientist hypothesis-search report
    does, assumes what is in dispute. Resolving it needs pre-symptomatic
    longitudinal cohorts - for instance EBV seroconverters carrying
    HLA-DRB1*15:01 - followed with serial imaging and paired immune-activation
    and CNS-injury biomarkers.
  evidence:
  - reference: PMID:34156169
    reference_title: "Mechanistic underpinning of an inside-out concept for autoimmunity in multiple sclerosis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Data reviewed here corroborate the validity of this inside-out pathogenic concept for multiple sclerosis."
    explanation: >-
      States the competing position. The argument rests on non-human primate
      models, where the immune system is experienced rather than
      specific-pathogen-free, and on myelin-axon dissociation in normal-appearing
      white matter of MS brains. Review-level synthesis, hence OTHER.
  - reference: PMID:35285112
    reference_title: "Ermin deficiency leads to compromised myelin, inflammatory milieu, and susceptibility to demyelinating insult."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Loss of Ermin in mice caused de-compacted and fragmented myelin sheaths and led to slower conduction along with progressive neurological deficits."
    explanation: >-
      The clearest experimental instance of the inside-out ordering: a
      primary defect in an oligodendrocyte-restricted cytoskeletal protein
      degrades myelin first, with microgliosis, astrogliosis and increased
      susceptibility to demyelinating insult following in aged animals.
  - reference: PMID:35285112
    reference_title: "Ermin deficiency leads to compromised myelin, inflammatory milieu, and susceptibility to demyelinating insult."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Supporting a possible role of Ermin deficiency in inflammatory white matter disorders, a rare inactivating mutation in the ERMN gene was identified in multiple sclerosis patients."
    explanation: >-
      The human anchor for the same model, and its limit: a single rare
      inactivating ERMN variant found in MS patients. A rare variant in a
      polygenic disease shows that a primary myelin defect can occur in MS, not
      that it is the usual initiating event.

references:
- reference: DOI:10.1038/s41392-025-02415-4
  title: "Multiple sclerosis: molecular pathogenesis and therapeutic intervention"
  found_in:
  - Multiple_Sclerosis-deep-research-cyberian-codex.md
  - Multiple_Sclerosis-deep-research-falcon.md
  findings: []
- reference: DOI:10.1177/11795735241249693
  title: "From progression to progress: The future of multiple sclerosis"
  found_in:
  - Multiple_Sclerosis-deep-research-cyberian-codex.md
  - Multiple_Sclerosis-deep-research-falcon.md
  findings: []
- reference: DOI:10.1177/13524585241301303
  title: Imaging Outcomes for Phase 2 Trials Targeting Compartmentalized Inflammation
  found_in:
  - Multiple_Sclerosis-deep-research-cyberian-codex.md
  - Multiple_Sclerosis-deep-research-falcon.md
  findings: []
- reference: DOI:10.14288/1.0444003
  title: Vaccination against gammaherpesvirus attenuates viral enhanced disease in a murine model of multiple sclerosis
  found_in:
  - Multiple_Sclerosis-deep-research-cyberian-codex.md
  - Multiple_Sclerosis-deep-research-falcon.md
  findings: []
- reference: DOI:10.3390/ijms26030884
  title: "A Window into New Insights on Progression Independent of Relapse Activity in Multiple Sclerosis: Role of Therapies and Current Perspective"
  found_in:
  - Multiple_Sclerosis-deep-research-cyberian-codex.md
  - Multiple_Sclerosis-deep-research-falcon.md
  findings: []
- reference: PMID:37266405
  title: "Moving forward through the in silico modeling of multiple sclerosis: Treatment layer implementation and validation."
- reference: PMID:38974971
  title: "The virtual multiple sclerosis patient."
- reference: PMID:40317832
  title: "Mapping Brain Lesions to Conduction Delays: The Next Step for Personalized Brain Models in Multiple Sclerosis."
datasets:
# EBI Single Cell Expression Atlas re-analysis of the Absinta et al. chronic-active-MS lesion atlas
- accession: scea:E-GEOD-180759
  title: Single-nucleus RNA-seq of the demyelinated white-matter lesion edge in chronic active multiple sclerosis
  description: >-
    EBI Single Cell Expression Atlas harmonized re-analysis (194,181 nuclei) of the
    Absinta et al. MRI-informed single-nucleus RNA-seq profiling of the edge of
    demyelinated white-matter lesions at various stages of inflammation. Defines
    "microglia inflamed in MS" (MIMS) and "astrocytes inflamed in MS" glial states
    with neurodegenerative programming at the chronically inflamed lesion rim, and
    implicates complement component 1q (C1q) as a mediator of MIMS activation —
    single-cell resolution of the compartmentalized, smouldering inflammation that
    underlies progression independent of relapse activity.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: SINGLE_CELL_RNA_SEQ
  sample_types:
  - preferred_term: demyelinated white-matter lesion tissue
    tissue_term:
      preferred_term: white matter
      term:
        id: UBERON:0002316
        label: white matter
  conditions:
  - chronic active multiple sclerosis lesion edge
  - demyelinated white matter
  platform: single-nucleus RNA-seq (10x Genomics)
  publication: PMID:34497421
  evidence:
  - reference: PMID:34497421
    reference_title: "A lymphocyte-microglia-astrocyte axis in chronic active multiple sclerosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MRI-informed single-nucleus RNA sequencing to profile the edge of demyelinated white matter lesions at various stages of inflammation"
    explanation: >-
      Human single-nucleus RNA-seq of the chronic active lesion edge (harmonized
      as SCEA E-GEOD-180759) resolves the disease-specific microglial (MIMS) and
      astrocytic states driving compartmentalized inflammation at the paramagnetic
      rim, a leading mechanism of non-relapsing MS progression.
  notes: >-
    Aggregator provenance: the harmonized re-analysis is hosted by the EBI Single
    Cell Expression Atlas (accession E-GEOD-180759); the primary deposit is GEO
    GSE180759 and the underlying study is Absinta et al., Nature 2021
    (PMID:34497421, DOI:10.1038/s41586-021-03892-7). The study additionally used a
    mouse EAE model for C1q validation; only the human lesion snRNA-seq is cited
    here (evidence_source HUMAN_CLINICAL).
- accession: geo:GSE306738
  title: Childhood Adversity, Allostatic Load, and Epigenetic Signatures in Pediatric and Adult-onset Multiple Sclerosis
  description: Childhood adversity has an impact on multiple sclerosis (MS) onset, clinical severity and progression, but our understanding of potentially related biological pathways is limited. This study evaluated 60 individuals with either pediatric-onset MS (POMS) or adult-onset MS (AOMS) and tested the association between personal history of childhood adversity and clinical MS outcomes, current indicators of allostatic load, and epigenetic signatures.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: METHYLATION
  sample_count: 53
  publication: PMID:41728265
  notes: Identified by GEO DataSets index search for Multiple Sclerosis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE310754
  title: DNA methylation changes in PBMCs of multiple sclerosis patients on glatiramer acetate therapy
  description: DNA methylation is a universal epigenetic mechanism involved in the regulation of gene expression in both normal physiological conditions and various pathologies. It has been demonstrated that the development of multiple sclerosis (MS) is accompanied by significant alterations in DNA methylation profiles in the blood immune cells of patients. Studies investigating genome-wide DNA methylation changes during therapy for MS patients using immunomodulatory drugs are limited, and for glatiramer acetate (GA), such investigations have not been conducted at all.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: METHYLATION
  sample_count: 12
  publication: PMID:42196591
  notes: Identified by GEO DataSets index search for Multiple Sclerosis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE328265
  title: A CSF Disease-Associated Macrophage Signature defines Progressive Multiple Sclerosis
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 31
  publication: PMID:42129775
  notes: Identified by GEO DataSets index search for Multiple Sclerosis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: ega:EGAS00000000022
  title: WTCCC case-control study for Multiple Sclerosis
  description: WTCCC genome-wide case-control association study for Multiple Sclerosis (MS) using the 1958 British Birth Cohort collection as controls.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Multiple Sclerosis"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00000000023
  title: WTCCC case-control study for Multiple Sclerosis - Combined controls
  description: WTCCC genome-wide accosication study for Multiple Sclerosis (MS) - Combined controls
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Multiple Sclerosis"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00000000101
  title: The Genetic Analysis of multiple sclerosis
  description: We created these data in order to identify genetic variants associated with increased susceptibility to multiple sclerosis. Cases from many parts of the world were genotyped with the Illumina 660 chip along with Swedish controls. In our analysis we also used control data from the WTCCC2 common UK controls and from other published studies.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Multiple Sclerosis"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: metabolomics_workbench:ST002415
  title: Proteomics and metabolomics of multiple sclerosis
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Multiple Sclerosis"). Retrieved 2026-08-02.
- accession: metabolomics_workbench:ST002416
  title: Proteomics and metabolomics of multiple sclerosis (Part 2)
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Multiple Sclerosis"). Retrieved 2026-08-02.
- accession: massive:MSV000086842
  title: The B Cell Repertoire in Multiple Sclerosis Reveals Molecular Mimicry between EBNA1 and GlialCAM
  description: This data set contains the mass spectrometry raw files for the paper The B Cell Repertoire in Multiple Sclerosis Reveals Molecular Mimicry between EBNA1 and GlialCAM. In multiple sclerosis (MS) intrathecal B lymphocytes are directly involved in inflammation and secrete oligoclonal immunoglobulin. However, our understanding of their phenotype, function, and antigen-specificity in MS is incomplete. Molecular mimicry to viruses and self-antigens could be a trigger of autoimmunity.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Multiple Sclerosis"). Retrieved 2026-08-02.